US20060002837A1 - Processes for making rare earth metal oxycarbonates - Google Patents
Processes for making rare earth metal oxycarbonates Download PDFInfo
- Publication number
- US20060002837A1 US20060002837A1 US11/181,609 US18160905A US2006002837A1 US 20060002837 A1 US20060002837 A1 US 20060002837A1 US 18160905 A US18160905 A US 18160905A US 2006002837 A1 US2006002837 A1 US 2006002837A1
- Authority
- US
- United States
- Prior art keywords
- lanthanum
- phosphate
- solution
- present
- rare earth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 230000008569 process Effects 0.000 title claims description 59
- 229910052761 rare earth metal Inorganic materials 0.000 title claims description 29
- 150000002910 rare earth metals Chemical class 0.000 title claims description 19
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical group Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims description 38
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 36
- 239000012065 filter cake Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 19
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 18
- -1 rare earth chloride Chemical class 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 8
- 238000003801 milling Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 100
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract description 90
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 89
- 239000010452 phosphate Substances 0.000 abstract description 88
- 229910052746 lanthanum Inorganic materials 0.000 abstract description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 47
- 239000002245 particle Substances 0.000 abstract description 40
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 13
- 239000012530 fluid Substances 0.000 abstract description 11
- 229910052751 metal Inorganic materials 0.000 abstract description 10
- 239000002184 metal Substances 0.000 abstract description 10
- 150000002909 rare earth metal compounds Chemical class 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 201000005991 hyperphosphatemia Diseases 0.000 abstract description 6
- 229910021645 metal ion Inorganic materials 0.000 abstract description 5
- 150000002739 metals Chemical class 0.000 abstract description 4
- 229910052684 Cerium Inorganic materials 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 3
- 229910001463 metal phosphate Inorganic materials 0.000 abstract description 3
- 229910052727 yttrium Inorganic materials 0.000 abstract description 3
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 75
- 150000001875 compounds Chemical class 0.000 description 69
- 239000000047 product Substances 0.000 description 48
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 44
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 229910002226 La2O2 Inorganic materials 0.000 description 26
- 238000001354 calcination Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000013078 crystal Substances 0.000 description 23
- 239000013067 intermediate product Substances 0.000 description 23
- 229910009112 xH2O Inorganic materials 0.000 description 21
- 229910017583 La2O Inorganic materials 0.000 description 20
- 150000002604 lanthanum compounds Chemical class 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000001704 evaporation Methods 0.000 description 19
- 230000008020 evaporation Effects 0.000 description 19
- 239000000725 suspension Substances 0.000 description 18
- 239000004408 titanium dioxide Substances 0.000 description 18
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 16
- 238000001878 scanning electron micrograph Methods 0.000 description 16
- 229910002249 LaCl3 Inorganic materials 0.000 description 15
- JEROREPODAPBAY-UHFFFAOYSA-N [La].ClOCl Chemical compound [La].ClOCl JEROREPODAPBAY-UHFFFAOYSA-N 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 15
- 239000007921 spray Substances 0.000 description 15
- 239000011550 stock solution Substances 0.000 description 15
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical class [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 14
- 229910052698 phosphorus Inorganic materials 0.000 description 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 12
- 238000002441 X-ray diffraction Methods 0.000 description 12
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 12
- 229960001633 lanthanum carbonate Drugs 0.000 description 12
- 239000011574 phosphorus Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 9
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- JLRJWBUSTKIQQH-UHFFFAOYSA-K lanthanum(3+);triacetate Chemical compound [La+3].CC([O-])=O.CC([O-])=O.CC([O-])=O JLRJWBUSTKIQQH-UHFFFAOYSA-K 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000012527 feed solution Substances 0.000 description 6
- KTUFCUMIWABKDW-UHFFFAOYSA-N oxo(oxolanthaniooxy)lanthanum Chemical compound O=[La]O[La]=O KTUFCUMIWABKDW-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 229910052785 arsenic Inorganic materials 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 150000002484 inorganic compounds Chemical class 0.000 description 5
- 229910010272 inorganic material Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical compound O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 238000004438 BET method Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000013059 nephrectomy Methods 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 229910001477 LaPO4 Inorganic materials 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 229910052787 antimony Inorganic materials 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XFVGXQSSXWIWIO-UHFFFAOYSA-N chloro hypochlorite;titanium Chemical compound [Ti].ClOCl XFVGXQSSXWIWIO-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- LQFNMFDUAPEJRY-UHFFFAOYSA-K lanthanum(3+);phosphate Chemical compound [La+3].[O-]P([O-])([O-])=O LQFNMFDUAPEJRY-UHFFFAOYSA-K 0.000 description 2
- 229910052745 lead Inorganic materials 0.000 description 2
- 239000011817 metal compound particle Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229910010270 TiOCl2 Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910001439 antimony ion Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- LULLIKNODDLMDQ-UHFFFAOYSA-N arsenic(3+) Chemical compound [As+3] LULLIKNODDLMDQ-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical class O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002603 lanthanum Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 150000003609 titanium compounds Chemical class 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/28—Treatment of water, waste water, or sewage by sorption
- C02F1/281—Treatment of water, waste water, or sewage by sorption using inorganic sorbents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/0203—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04
- B01J20/0207—Compounds of Sc, Y or Lanthanides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/0203—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04
- B01J20/0274—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04 characterised by the type of anion
- B01J20/0277—Carbonates of compounds other than those provided for in B01J20/043
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/0203—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04
- B01J20/0274—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04 characterised by the type of anion
- B01J20/0288—Halides of compounds other than those provided for in B01J20/046
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28057—Surface area, e.g. B.E.T specific surface area
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3078—Thermal treatment, e.g. calcining or pyrolizing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3234—Inorganic material layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3234—Inorganic material layers
- B01J20/3236—Inorganic material layers containing metal, other than zeolites, e.g. oxides, hydroxides, sulphides or salts
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/247—Carbonates
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/253—Halides
- C01F17/271—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/36—Compounds of titanium
- C09C1/3607—Titanium dioxide
- C09C1/3653—Treatment with inorganic compounds
- C09C1/3661—Coating
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/60—Compounds characterised by their crystallite size
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/90—Other properties not specified above
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/001—Processes for the treatment of water whereby the filtration technique is of importance
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2101/00—Nature of the contaminant
- C02F2101/10—Inorganic compounds
- C02F2101/103—Arsenic compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2101/00—Nature of the contaminant
- C02F2101/10—Inorganic compounds
- C02F2101/105—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2101/00—Nature of the contaminant
- C02F2101/10—Inorganic compounds
- C02F2101/20—Heavy metals or heavy metal compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present invention relates to rare earth metal compounds, particularly rare earth metal compounds having a porous structure.
- the present invention also includes methods of making the porous rare earth metal compounds and methods of using the compounds of the present invention.
- the compounds of the present invention can be used to bind or absorb metals such as arsenic, selenium, antimony and metal ions such as arsenic III + and V + .
- the compounds of the present invention may therefore find use in water filters or other devices or methods to remove metals and metal ions from fluids, especially water.
- the compounds of the present invention are also useful for binding or absorbing anions such as phosphate in the gastrointestinal tract of mammals. Accordingly, one use of the compounds of the present invention is to treat high serum phosphate levels in patients with end-stage renal disease undergoing kidney dialysis.
- the compounds may be provided in a filter that is fluidically connected with a kidney dialysis machine such that the phosphate content in the blood is reduced after passing through the filter.
- the compounds can be used to deliver a lanthanum or other rare-earth metal compound that will bind phosphate present in the gut and prevent its transfer into the bloodstream.
- Compounds of the present invention can also be used to deliver drugs or to act as a filter or absorber in the gastrointestinal tract or in the blood stream.
- the materials can be used to deliver inorganic chemicals in the gastrointestinal tract or elsewhere.
- porous particle structure and the high surface area are beneficial to high absorption rates of anions.
- these properties permit the compounds of the present invention to be used to bind phosphate directly in a filtering device fluidically connected with kidney dialysis equipment.
- U.S. Pat. No. 5,968,976 discloses a lanthanum carbonate hydrate to remove phosphate in the gastrointestinal tract and to treat hyperphosphatemia in patients with renal failure. It also shows that hydrated lanthanum carbonates with about 3 to 6 molecules of crystal water provide the highest removal rates.
- U.S. Pat. No. 6,322,895 discloses a form of silicon with micron-sized or nano-sized pores that can be used to release drugs slowly in the body.
- U.S. Pat. No. 5,782,792 discloses a method for the treatment of rheumatic arthritis where a “protein A immunoadsorbent” is placed on silica or another inert binder in a cartridge to physically remove antibodies from the bloodstream.
- the specific surface area of compounds according to the present invention as measured by the BET method, varies depending on the method of preparation, and has a significant effect on the properties of the product.
- the specific properties of the resulting compound can be adjusted by varying one or more parameters in the method of making the compound.
- the compounds of the present invention have a BET specific surface area of at least about 10 m 2 /g and may have a BET specific surface area of at least about 20 m 2 /g and alternatively may have a BET specific surface area of at least about 35 m 2 ⁇ g.
- the compounds have a BET specific surface area within the range of about 10 m 2 /g and about 40 m 2 /g.
- the compounds of the present invention and in particular, the lanthanum compounds and more particularly the lanthanum oxycarbonates of the present invention exhibit phosphate binding or removal of at least 40% of the initial concentration of phosphate after ten minutes. Desirably, the lanthanum compounds exhibit phosphate binding or removal of at least 60% of the initial concentration of phosphate after ten minutes. In other words, the lanthanum compounds and in particular, the lanthanum compounds and more particularly the lanthanum oxycarbonates of the present invention exhibit a phosphate binding capacity of at least 45 mg of phosphate per gram of lanthanum compound.
- the lanthanum compounds exhibit a phosphate binding capacity of at least 50 mg PO 4 /g of lanthanum compound, more suitably, a phosphate binding capacity of at least 75 mg PO 4 /g of lanthanum compound.
- the lanthanum compounds exhibit a phosphate binding capacity of at least 100 mg PO 4 /g of lanthanum compound, more desirably, a phosphate binding capacity of at least 110 mg PO 4 /g of lanthanum compound.
- rare earth metal compounds and in particular, rare earth metal oxychlorides and oxycarbonates are provided.
- the oxycarbonates may be hydrated or anhydrous. These compounds may be produced according to the present invention as particles having a porous structure.
- the rare earth metal compound particles of the present invention may conveniently be produced within a controllable range of surface areas with resultant variable and controllable adsorption rates of ions.
- the porous particles or porous structures of the present invention are made of nano-sized to micron-sized crystals with controllable surface areas.
- the rare earth oxychloride is desirably lanthanum oxychloride (LaOCl).
- the rare earth oxycarbonate hydrate is desirably lanthanum oxycarbonate hydrate (La 2 O(CO 3 ) 2 .xH 2 O where x is from and including 2 to and including 4). This compound will further be referred to in this text as La 2 O(CO 3 ) 2 .xH 2 O.
- the anhydrous rare earth oxycarbonate is desirably lanthanum oxycarbonate La 2 O 2 CO 3 or La 2 CO 5 of which several crystalline forms exist. The lower temperature form will be identified as La 2 O 2 CO 3 and the form obtained at higher temperature or after a longer calcination time will be identified as La 2 CO 5 .
- lanthanum oxycarbonate may be present as a mixture of the hydrate and the anhydrous form.
- anhydrous lanthanum oxycarbonate may be present as a mixture of La 2 O 2 CO 3 and La 2 CO 5 and may be present in more than a single crystalline form.
- One method of making the rare earth metal compound particles includes making a solution of rare earth metal chloride, subjecting the solution to a substantially total evaporation process using a spray dryer or other suitable equipment to form an intermediate product, and calcining the obtained intermediate product at a temperature between about 5000 and about 1200° C.
- the product of the calcination step may be washed, filtered, and dried to make a suitable finished product.
- the intermediate product may be milled in a horizontal or vertical pressure media mill to a desired surface area and then further spray dried or dried by other means to produce a powder that may be further washed and filtered.
- An alternative method of making the rare earth metal compounds, particularly rare earth metal anhydrous oxycarbonate particles includes making a solution of rare earth metal acetate, subjecting the solution to a substantially total evaporation process using a spray dryer or other suitable equipment to make an intermediate product, and calcining the obtained intermediate product at a temperature between about 400° C. and about 700° C.
- the product of the calcination step may be washed, filtered, and dried to make a suitable finished product.
- the intermediate product may be milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- the rare earth metal oxycarbonate hydrate particles can be made by successively making a solution of rare earth chloride, subjecting the solution to a slow, steady feed of a sodium carbonate solution at a temperature between about 30° and about 90° C. while mixing, then filtering and washing the precipitate to form a filter cake, then drying the filter cake at a temperature of about 100° to 120° C. to produce the desired rare earth oxycarbonate hydrate species.
- the filter cake may be sequentially dried, slurried, and milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- the process for making rare earth metal oxycarbonate hydrate particles may be modified to produce anhydrous particles.
- This modification includes subjecting the dried filter cake to a thermal treatment at a specified temperature between about 400° C. to about 700° C. and for a specified time between 1 h and 48 h.
- the product of the thermal treatment may be slurried and milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- compounds of the present invention may be used to treat patients with hyperphosphatemia.
- the compounds may be made into a form that may be delivered to a mammal and that may be used to remove phosphate from the gut or decrease phosphate absorption into the blood stream.
- the compounds may be formulated to provide an orally ingestible form such as a liquid solution or suspension, a tablet, capsule, gelcap, or other suitable and known oral form.
- the present invention contemplates a method for treating hyperphosphatemia that comprises providing an effective amount of a compound of the present invention.
- compounds made according to this invention as a porous structure of sufficient mechanical strength may be placed in a device fluidically connected to a dialysis machine through which the blood flows, to directly remove phosphate by reaction of the rare-earth compound with phosphate in the bloodstream.
- the present invention therefore contemplates a device having an inlet and an outlet with one or more compounds of the present invention disposed between the inlet and the outlet.
- the present invention also contemplates a method of reducing the amount of phosphate in blood that comprises contacting the blood with one or more compounds of the present invention for a time sufficient to reduce the amount of phosphate in the blood.
- the compounds of the present invention may be used as a substrate for a filter having an inlet and outlet such that the compounds of the present invention are disposed between the inlet and the outlet.
- a fluid containing a metal, metal ion, phosphate or other ion may be passed from the inlet to contact the compounds of the present invention and through the outlet.
- a method of reducing the content of a metal in a fluid comprises flowing the fluid through a filter that contains one or more compounds of the present invention to reduce the amount of metal present in the water.
- FIG. 1 is a general flow sheet of a process according to the present invention that produces LaOCl (lanthanum oxychloride).
- FIG. 2 is a flow sheet of a process according to the present invention that produces a coated titanium dioxide structure.
- FIG. 3 is a flow sheet of a process according to the present invention that produces lanthanum oxycarbonate
- FIG. 4 is a graph showing the percentage of phosphate removed from a solution as a function of time by LaO(CO 3 ) 2 .xH 2 O, (where x is from and including 2 to and including 4), made according to the process of the present invention, as compared to the percentage of phosphate removed by commercial grade La carbonate La 2 (CO 3 ) 3 .4H 2 O in the same conditions.
- FIG. 5 is a graph showing the amount of phosphate removed from a solution as a function of time per g of a lanthanum compound used as a drug to treat hyperphosphatemia.
- the drug in one case is La 2 O(CO 3 ) 2 .xH 2 O (where x is from and including 2 to and including 4), made according to the process of the present invention.
- the drug is commercial grade La carbonate La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 6 is a graph showing the amount of phosphate removed from a solution as a function of time per g of a lanthanum compound used as a drug to treat hyperphosphatemia.
- the drug in one case is La 2 O 2 CO 3 made according to the process of the present invention. In the comparative case the drug is commercial grade La carbonate La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 7 is a graph showing the percentage of phosphate removed as a function of time by La 2 O 2 CO 3 made according to the process of the present invention, as compared to the percentage of phosphate removed by commercial grade La carbonate La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 8 is a graph showing a relationship between the specific surface area of the oxycarbonates made following the process of the present invention and the amount of phosphate bound or removed from solution 10 min after the addition of the oxycarbonate.
- FIG. 9 is a graph showing a linear relationship between the specific surface area of the oxycarbonates of this invention and the first order rate constant calculated from the initial rate of reaction of phosphate.
- FIG. 10 is a flow sheet of a process according to the present invention that produces lanthanum oxycarbonate hydrate La 2 (CO 3 ) 2 .xH 2 O
- FIG. 11 is a flow sheet of a process according to the present invention that produces anhydrous lanthanum oxycarbonate La 2 O 2 CO 3 or La 2 CO 5 .
- FIG. 12 is a scanning electron micrograph of lanthanum oxychloride, made following the process of the present invention.
- FIG. 13 is an X-Ray diffraction scan of lanthanum oxychloride LaOCl made according to the process of the present invention and compared with a standard library card of lanthanum oxychloride.
- FIG. 14 is a graph showing the percentage of phosphate removed from a solution as a function of time by LaOCl made according to the process of the present invention, as compared to the amount of phosphate removed by commercial grades of La carbonate La 2 (CO 3 ) 3 —H 2 O and La 2 (CO 3 ) 3 .4H 2 O in the same conditions.
- FIG. 15 shows a scanning electron micrograph of La 2 O(CO 3 ) 2 Ox H 2 O, where x is from and including 2 to and including 4.
- FIG. 16 is an X-Ray diffraction scan of La 2 O(CO 3 ) 2 .xH 2 O produced according to the present invention and includes a comparison with a “library standard” of La 2 O(CO 3 ) 2 .xH 2 O where x is from and including 2 to and including 4.
- FIG. 17 is a graph showing the rate of removal of phosphorous from a solution by La 2 O(CO 3 )2.xH 2 O compared to the rate obtained with commercially available La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .H 2 O in the same conditions.
- FIG. 18 is a scanning electron micrograph of anhydrous lanthanum oxycarbonate La 2 O 2 CO 3 .
- FIG. 19 is an X-Ray diffraction scan of anhydrous La 2 O 2 CO 3 produced according to the present invention and includes a comparison with a “library standard” of La 2 O 2 CO 3 .
- FIG. 20 is a graph showing the rate of phosphorous removal obtained with La 2 O 2 CO 3 made following the process of the present invention and compared to the rate obtained for commercially available La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .H 2 O.
- FIG. 21 is a scanning electron micrograph of La 2 CO 5 made according to the process of the present invention.
- FIG. 22 is an X-Ray diffraction scan of anhydrous La 2 CO 5 produced according to the present invention and includes a comparison with a “library standard” of La 2 CO 5 .
- FIG. 23 is a graph showing the rate of phosphorous removal obtained with La 2 CO 5 made following the process of the present invention and compared to the rate obtained for commercially available La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 30.4 H 2 O.
- FIG. 24 is a scanning electron micrograph of TiO 2 support material made according to the process of the present invention.
- FIG. 25 is a scanning electron micrograph of a TiO 2 structure coated with LaOCl, made according to the process of the present invention, calcined at 800° C.
- FIG. 26 is a scanning electron micrograph of a TiO 2 structure coated with LaOCl, made according to the process of the present invention, calcined at 600° C.
- FIG. 27 is a scanning electron micrograph of a TiO 2 structure coated with LaOCl, made according to the process of the present invention, calcined at 900° C.
- FIG. 28 shows X-Ray scans for TiO 2 coated with LaOCl and calcined at different temperatures following the process of the present invention, and compared to the X-Ray scan for pure LaOCl.
- FIG. 29 shows the concentration of lanthanum in blood plasma as a function of time, for dogs treated with lanthanum oxycarbonates made according to the process of the present invention.
- FIG. 30 shows the concentration of phosphorous in urine as a function of time in rats treated with lanthanum oxycarbonates made according to the process of the present invention, and compared to phosphorus concentration measured in untreated rats.
- FIG. 31 shows a device having an inlet, an outlet, and one or more compounds of the present invention disposed between the inlet and the outlet.
- lanthanum compounds While the description will generally refer to lanthanum compounds, the use of lanthanum is merely for ease of description and is not intended to limit the invention and claims solely to lanthanum compounds. In fact, it is contemplated that the process and the compounds described in the present specification is equally applicable to rare earth metals other than lanthanum such as Ce and Y.
- a process for making a rare earth oxychloride compound, and, in particular a lanthanum oxychloride compound according to one embodiment of the present invention is shown.
- the source of lanthanum chloride may be any suitable source and is not limited to any particular source.
- One source of lanthanum chloride solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution.
- Another source is to dissolve lanthanum oxide in a hydrochloric acid solution.
- the lanthanum chloride solution is evaporated to form an intermediate product.
- the evaporation 20 is conducted under conditions to achieve substantially total evaporation. Desirably, the evaporation is conducted at a temperature higher than the boiling point of the feed solution (lanthanum chloride) but lower than the temperature where significant crystal growth occurs.
- the resulting intermediate product may be an amorphous solid formed as a thin film or may have a spherical shape or a shape as part of a sphere.
- substantially total evaporation or “substantially complete evaporation” as used in the specification and claims refer to evaporation such that the resulting solid intermediate contains less than 15% free water, desirably less than 10% free water, and more desirably less than 1% free water.
- free water is understood and means water that is not chemically bound and can be removed by heating at a temperature below 150° C. After substantially total evaporation or substantially complete evaporation, the intermediate product will have no visible moisture present.
- the evaporation step may be conducted in a spray dryer.
- the intermediate product will consist of a structure of spheres or parts of spheres.
- the spray dryer generally operates at a discharge temperature between about 120° C. and about 500° C.
- the intermediate product may then be calcined in any suitable calcination apparatus 30 by raising the temperature to a temperature between about 500° C. to about 1200° C. for a period of time from about 2 to about 24 h and then cooling to room temperature.
- the cooled product may be washed 40 by immersing it in water or dilute acid, to remove any water-soluble phase that may still be present after the calcination step 30 .
- the temperature and the length of time of the calcination process may be varied to adjust the particle size and the reactivity of the product.
- the particles resulting from calcination generally have a size between 1 and 1000 ⁇ m.
- the calcined particles consist of individual crystals, bound together in a structure with good physical strength and a porous structure.
- the individual crystals forming the particles generally have a size between 20 nm and 10 ⁇ m.
- a feed solution of titanium chloride or titanium oxychloride is provided by any suitable source.
- One source is to dissolve anhydrous titanium chloride in water or in a hydrochloric acid solution.
- Chemical control agents or additives 104 may be introduced to this feed solution to influence the crystal form and the particle size of the final product.
- One chemical additive is sodium phosphate Na 3 PO 4 .
- the feed solution of titanium chloride or titanium oxychloride is mixed with the optional chemical control agent 104 in a suitable mixing step 110 . The mixing may be conducted using any suitable known mixer.
- the feed solution is evaporated to form an intermediate product, which in this instance is titanium dioxide (TiO 2 ).
- the evaporation 120 is conducted at a temperature higher than the boiling point of the feed solution but lower than the temperature where significant crystal growth occurs and to achieve substantially total evaporation.
- the resulting intermediate product may desirably be an amorphous solid formed as a thin film and may have a spherical shape or a shape as part of a sphere.
- the intermediate product may then be calcined in any suitable calcination apparatus 130 by raising the temperature to a temperature between about 400° C. to about 1200° C. for a period of time from about 2 to about 24 h and then cooling to room temperature (25° C.).
- the cooled product is then washed 140 by immersing it in water or dilute acid, to remove traces of any water-soluble phase that may still be present after the calcination step.
- the method of manufacture of the intermediate product according to the present invention can be adjusted and chosen to make a structure with the required particle size and porosity.
- the evaporation step 120 and the calcination step 130 can be adjusted for this purpose.
- the particle size and porosity can be adjusted to make the structure of the intermediate product suitable to be used as an inert filter in the bloodstream.
- the washed TiO 2 product is then suspended or slurried in a solution of an inorganic compound.
- a desirable inorganic compound is a rare-earth or lanthanum compound, and in particular lanthanum chloride.
- This suspension of TiO 2 in the inorganic compound solution is again subjected to total evaporation 160 under conditions in the same range as defined in step 120 and to achieve substantially total evaporation.
- the evaporation steps 120 and 160 may be conducted in a spray drier.
- the inorganic compound will precipitate as a salt, an oxide, or an oxy-salt. If the inorganic compound is lanthanum chloride, the precipitated product will be lanthanum oxychloride. If the original compound is lanthanum acetate, the precipitated product will be lanthanum oxide.
- the product of step 160 is further calcined 170 at a temperature between 500° and 1100° C. for a period of 2 to 24 h.
- the temperature and the time of the calcination process influence the properties and the particle size of the product.
- the product may be washed 180 .
- the resulting product can be described as crystals of lanthanum oxychloride or lanthanum oxide formed on a TiO 2 substrate.
- the resulting product may be in the form of hollow thin-film spheres or parts of spheres.
- the spheres will have a size of about 1 ⁇ m to 1000 ⁇ m and will consist of a structure of individual bound particles.
- the individual particles have a size between 20 nm and 10 ⁇ m.
- the product When the final product consists of crystals of lanthanum oxychloride on a TiO 2 substrate, these crystals may be hydrated. It has been found that this product will effectively react with phosphate and bind it as an insoluble compound. It is believed that, if this final product is released in the human stomach and gastrointestinal tract, the product will bind the phosphate that is present and decrease the transfer of phosphate from the stomach and gastrointestinal tract to the blood stream. Therefore, the product of this invention may be used to limit the phosphorous content in the bloodstream of patients on kidney dialysis.
- a process for making anhydrous lanthanum oxycarbonate is shown in FIG. 3 .
- a solution of lanthanum acetate is made by any method.
- One method to make the lanthanum acetate solution is to dissolve commercial lanthanum acetate crystals in water or in an HCl solution.
- the lanthanum acetate solution is evaporated to form an intermediate product.
- the evaporation 220 is conducted at a temperature higher than the boiling point of the lanthanum acetate solution but lower than the temperature where significant crystal growth occurs and under conditions to achieve substantially total evaporation.
- the resulting intermediate product may desirably be an amorphous solid formed as a thin film and may have a spherical shape or a shape as part of a sphere.
- the intermediate product may then be calcined in any suitable calcination apparatus 230 by raising the temperature to a temperature between about 400° C. to about 800° C. for a period of time from about 2 to about 24 h and then cooled to room temperature.
- the cooled product may be washed 240 by immersing it in water or dilute acid, to remove any water-soluble phase that may still be present after the calcination step.
- the temperature and the length of time of the calcination process may be varied to adjust the particle size and the reactivity of the product.
- the particles resulting from the calcination generally have a size between 1 and 1000 ⁇ m.
- the calcined particles consist of individual crystals, bound together in a structure with good physical strength and a porous structure.
- the individual crystals generally have a size between 20 nm and 10 ⁇ m.
- the products made by methods shown in FIGS. 1, 2 , and 3 comprise ceramic particles with a porous structure. Individual particles are in the micron size range. The particles are composed of crystallites in the nano-size range, fused together to create a structure with good strength and porosity.
- the particles made according to the process of the present invention have the following common properties:
- lanthanum oxycarbonates have been prepared by different methods. It has been found that, depending on the method of preparation, lanthanum oxycarbonate compounds with widely different reaction rates are obtained.
- a desirable lanthanum oxycarbonate is La 2 O(CO 3 ) 2 .xH 2 O, where 2 ⁇ x ⁇ 4. This lanthanum oxycarbonate is preferred because it exhibits a relatively high rate of removal of phosphate.
- the amount of lanthanum oxycarbonate powder is such that the amount of La in suspension is 3 times the stoichiometric amount needed to react completely with the phosphate.
- Samples of the suspension are taken at intervals, through a filter that separated all solids from the liquid. The liquid sample is analyzed for phosphorous.
- FIG. 4 shows that after 10 min, La 2 O(CO 3 ) 2 .xH 2 O has removed 86% of the phosphate in solution, whereas a commercial hydrated La carbonate La 2 (CO 3 ) 3 .H 2 O removes only 38% of the phosphate in the same experimental conditions after the same time.
- FIG. 5 shows that the La 2 O(CO 3 ) 2 .xH 2 O depicted in FIG. 4 has a capacity of phosphate removal of 110 mg PO 4 removed/g of La compound after 10 min in the conditions described above, compared to 45 mg PO 4 /g for the commercial La carbonate taken as reference.
- La 2 O 2 CO 3 Another preferred lanthanum carbonate is the anhydrous La oxycarbonate La 2 O 2 CO 3 .
- This compound is preferred because of its particularly high binding capacity for phosphate, expressed as mg PO 4 removed/g of compound.
- FIG. 6 shows that La 2 O 2 CO 3 binds 120 mg PO 4 /g of La compound after 10 min, whereas La 2 (CO 3 ) 3 .4H 2 O used as reference only binds 45 mg PO 4 /g La compound.
- FIG. 7 shows the rate of reaction with phosphate of the oxycarbonate La 2 O 2 CO 3 . After 10 min of reaction, 73% of the phosphate had been removed, compared to 38% for commercial lanthanum carbonate used as reference.
- the table also shows the rate constant k 1 corresponding to the initial rate of reaction of phosphate, assuming the reaction is first order in phosphate concentration.
- the table gives the rate constant for the initial reaction rate, i.e. the rate constant calculated from the experimental points for the first minute of the reaction.
- FIG. 8 shows that there is a good correlation between the specific surface area and the amount of phosphate reacted after 10 min. It appears that in this series of tests, the most important factor influencing the rate of reaction is the surface area, independently of the composition of the oxycarbonate or the method of manufacture. A high surface area can be achieved by adjusting the manufacturing method or by milling a manufactured product.
- FIG. 9 shows that a good correlation is obtained for the same compounds by plotting the first order rate constant as given in Table I and the BET specific surface area.
- the correlation can be represented by a straight line going through the origin. In other words, within experimental error, the initial rate of reaction appears to be proportional to the phosphate concentration and also to the available surface area.
- the observed dependence on surface area and phosphate concentration may be explained by a nucleophilic attack of the phosphate ion on the La atom in the oxycarbonate, with resultant formation of lanthanum phosphate LaPO 4 .
- the reaction will be: 1 ⁇ 2 La 2 O 2 CO 3 +PO 4 3 ⁇ +2H 2 O ⁇ LaPO 4 +1 ⁇ 2 H 2 CO 3 +3OH ⁇
- the rate is limited by the diffusion of the PO 4 3 ⁇ ion to the surface of the oxycarbonate and the available area of oxycarbonate, the observed relationship expressed in FIG. 9 can be explained. This mechanism does not require La to be present as a dissolved species.
- the present reasoning also provides an explanation for the decrease of the reaction rate after the first minutes: the formation of lanthanum phosphate on the surface of the oxycarbonate decreases the area available for reaction.
- FIG. 10 another process for making lanthanum oxycarbonate and in particular, lanthanum oxycarbonate tetra hydrate, is shown.
- an aqueous solution of lanthanum chloride is made by any method.
- One method to make the solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution.
- Another method to make the lanthanum chloride solution is to dissolve lanthanum oxide in a hydrochloric acid solution.
- the LaCl 3 solution is placed in a well-stirred tank reactor.
- the LaCl 3 solution is then heated to 80° C.
- a previously prepared analytical grade sodium carbonate is steadily added over a period of 2 hours with vigorous mixing.
- the mass of sodium carbonate required is calculated at 6 moles of sodium carbonate per 2 moles of LaCl 3 .
- the resultant slurry or suspension is allowed to cure for 2 hours at 80° C.
- the suspension is then filtered and washed with demineralized water to produce a clear filtrate.
- the filter cake is placed in a convection oven at 105° C. for 2 hours or until a stable weight is observed.
- the initial pH of the LaCl 3 solution is 2, while the final pH of the suspension after cure is 5.5.
- a white powder is produced.
- the resultant powder is a lanthanum oxycarbonate four hydrate (La 2 O(CO 3 ) 2 .xH 2 O).
- the number of water molecules in this compound is approximate and may vary between 2 and 4 (and including 2 and 4).
- an aqueous solution of lanthanum chloride is made by any method.
- One method to make the solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution.
- Another method to make the lanthanum chloride solution is to dissolve lanthanum oxide in a hydrochloric acid solution.
- the LaCl 3 solution is placed in a well-stirred tank reactor.
- the LaCl 3 solution is then heated to 80° C.
- a previously prepared analytical grade sodium carbonate is steadily added over 2 hours with vigorous mixing.
- the mass of sodium carbonate required is calculated at 6 moles of sodium carbonate per 2 moles of LaCl 3 .
- the required mass of sodium carbonate solution is added the resultant slurry or suspension is allowed to cure for 2 hours at 80° C.
- the suspension is then washed and filtered removing NaCl (a byproduct of the reaction) to produce a clear filtrate.
- the filter cake is placed in a convection oven at 105° C. for 2 hours or until a stable weight is observed.
- the initial pH of the LaCl 3 solution is 2.2, while the final pH of the suspension after cure is 5.5.
- a white lanthanum oxycarbonate hydrate powder is produced.
- the lanthanum oxycarbonate hydrate is placed in an alumina tray, which is placed in a high temperature muffle furnace.
- the white powder is heated to 500° C. and held at that temperature for 3 hours.
- Anhydrous La 2 C 2 O 3 is formed.
- the anhydrous lanthanum oxycarbonate formed as indicated in the previous paragraph may be heated at 500° C. for 15 to 24 h instead of 3 h or at 600° C. instead of 500° C.
- the resulting product has the same chemical formula, but shows a different pattern in an X-Ray diffraction scan and exhibits a higher physical strength and a lower surface area.
- the product corresponding to a higher temperature or a longer calcination time is defined here as La 2 CO 5 .
- the device 500 may be in the form of a filter or other suitable container. Disposed between the inlet 502 and the outlet 504 is a substrate 506 in the form of a plurality of one or more compounds of the present invention.
- the device may be fluidically connected to a dialysis machine through which the blood flows, to directly remove phosphate by reaction of the rare-earth compound with phosphate in the bloodstream.
- the present invention also contemplates a method of reducing the amount of phosphate in blood that comprises contacting the blood with one or more compounds of the present invention for a time sufficient to reduce the amount of phosphate in the blood.
- the device 500 may be provided in a fluid stream so that a fluid containing a metal, metal ion, phosphate or other ion may be passed from the inlet 502 through the substrate 506 to contact the compounds of the present invention and out the outlet 504 .
- a method of reducing the content of a metal in a fluid comprises flowing the fluid through a device 500 that contains one or more compounds of the present invention to reduce the amount of metal present in the water.
- FIG. 12 shows a scanning electron micrograph of the product, enlarged 25,000 times. The micrograph shows a porous structure formed of needle-like particles. The X-Ray diffraction pattern of the product ( FIG. 13 ) shows that it consists of lanthanum oxychloride LaOCl.
- Example 1 To determine the reactivity of a commercial lanthanum with respect to phosphate, the relevant portion of Example 1 was repeated under the same conditions, except that commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O was used instead of the lanthanum oxychloride of the present invention. Additional curves on FIG. 14 show the rate of removal of phosphate corresponding to commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ).4H 2 O. FIG. 14 shows that the rate of removal of phosphate with the commercial lanthanum carbonate is faster at the beginning but slower after about 3 minutes.
- aqueous HCl solution having a volume of 334.75 ml and containing LaCl 3 (lanthanum chloride) at a concentration of 29.2 wt % as La 2 O 3 was added to a four liter beaker and heated to 80° C. with stirring.
- the initial pH of the LaCl 3 solution was 2.2.
- Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na 2 CO 3 ) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper, the filtrate was separated from the white powder product.
- FIG. 15 shows a scanning electron micrograph of the product, enlarged 120,000 times.
- the micrograph shows the needle-like structure of the compound.
- the X-Ray diffraction pattern of the product shows that it consists of hydrated lanthanum oxycarbonate hydrate (La 2 O(CO 3 ) 2 .xH 2 O), with 2 ⁇ x ⁇ 4.
- Example 3 To determine the reactivity of a commercial lanthanum with respect to phosphate, the second part of Example 3 was repeated under the same conditions, except that commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O was used instead of the lanthanum oxychloride of the present invention.
- FIG. 17 shows the rate of phosphate removed using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 17 shows the rate of phosphate removed using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 17 shows the rate of phosphate removed using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- aqueous HCl solution having a volume of 334.75 ml and containing LaCl 3 (lanthanum chloride) at a concentration of 29.2 wt % as La 2 O 3 was added to a 4 liter beaker and heated to 80° C. with stirring.
- the initial pH of the LaCl 3 solution was 2.2.
- Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na 2 CO 3 ) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper the filtrate was separated from the white powder product.
- the filter cake was mixed four times with 2 liters of distilled water and filtered to wash away the NaCl formed during the reaction.
- the washed filter cake was placed into a convection oven set at 105° C. for 2 hours until a stable weight was observed.
- the lanthanum oxycarbonate was placed in an alumina tray in a muffle furnace. The furnace temperature was ramped to 500° C. and held at that temperature for 3 hours.
- the resultant product was determined to be anhydrous lanthanum oxycarbonate La 2 O 2 CO 3 .
- FIG. 18 is a scanning electron micrograph of the structure, enlarged 60,000 times. The micrograph shows that the structure in this compound is made of equidimensional or approximately round particles of about 100 nm in size.
- FIG. 19 is an X-ray diffraction pattern showing that the product made here is an anhydrous lanthanum oxycarbonate written as La 2 O 2 CO 3 .
- Example 5 To determine the reactivity of a commercial lanthanum with respect to phosphate, the second part of Example 5 was repeated under the same conditions, except that commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O was used instead of the La 2 O 2 CO 3 of the present invention.
- FIG. 20 shows the rate of removal of phosphate using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 20 shows the rate of removal of phosphate using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 20 shows the rate of removal of phosphate using the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 21 shows a scanning electron micrograph of the product, enlarged 80,000 times.
- FIG. 22 shows the X-Ray diffraction pattern of the product and it shows that it consists of anhydrous lanthanum oxycarbonate. The X-Ray pattern is different from the pattern corresponding to Example 5, even though the chemical composition of the compound is the same. The formula for this compound is written as (La 2 CO 5 ). Comparing FIGS.
- 21 and 18 shows that the compound of the present example shows a structure of leaves and needles as opposed to the round particles formed in Example 5.
- the particles may be used in a device to directly remove phosphate from an aqueous or non-aqueous medium, e.g., the gut or the bloodstream.
- FIG. 23 shows the rate of phosphate removal for the commercial lanthanum carbonate La 2 (CO 3 ) 3 .H 2 O and La 2 (CO 3 ) 3 .4H 2 O.
- FIG. 24 is a scanning electron micrograph of the TiO 2 material obtained. It shows a porous structure with individual particles of about 250 nm connected in a structure. This structure shows good mechanical strength. This material can be used as an inert filtering material in a fluid stream such as blood.
- Example 9 The product of Example 9 is re-slurried into a solution of lanthanum chloride containing 100 g/l La.
- the slurry contains approximately 30% TiO 2 by weight.
- the slurry is spray dried in a spray dryer with an outlet temperature of 250° C.
- the product of the spray drier is further calcined at 800° C. for 5 h. It consists of a porous TiO 2 structure with a coating of nano-sized lanthanum oxychloride.
- FIG. 25 is a scanning electron micrograph of this coated product. The electron micrograph shows that the TiO 2 particles are several microns in size.
- the LaOCl is present as a crystallized deposit with elongated crystals, often about 1 ⁇ m long and 0.1 ⁇ m across, firmly attached to the TiO 2 catalyst support surface as a film of nano-size thickness.
- the LaOCl growth is controlled by the TiO 2 catalyst support structure. Orientation of rutile crystals works as a template for LaOCl crystal growth.
- the particle size of the deposit can be varied from the nanometer to the micron range by varying the temperature of the second calcination step.
- FIG. 26 is a scanning electron micrograph corresponding to calcination at 600° C. instead of 800° C. It shows LaOCl particles that are smaller and less well attached to the TiO 2 substrate.
- FIG. 27 is a scanning electron micrograph corresponding to calcination at 900° C. instead of 800° C. The product is similar to the product made at 800° C., but the LaOCl deposit is present as somewhat larger crystals and more compact layer coating the TiO2 support crystals.
- FIG. 28 shows the X-Ray diffraction patterns corresponding to calcinations at 600°, 800° and 900° C. The figure also shows the pattern corresponding to pure LaOCl. The peaks that do not appear in the pure LaOCl pattern correspond to rutile TiO 2 . As the temperature increases, the peaks tend to become higher and narrower, showing that the crystal size of the LaOCl as well as TiO 2 increases with the temperature.
- aqueous HCl solution having a volume of 334.75 ml and containing LaCl 3 (lanthanum chloride) at a concentration of 29.2 wt % as La 2 O 3 was added to a 4 liter beaker and heated to 80° C. with stirring.
- the initial pH of the LaCl 3 solution was 2.2.
- Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na 2 CO 3 ) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper the filtrate was separated from the white powder product.
- the filter cake was mixed four times, each with 2 liters of distilled water and filtered to wash away the NaCl formed during the reaction.
- the washed filter cake was placed into a convection oven set at 105° C. for 2 hours or until a stable weight was observed.
- the X-Ray diffraction pattern of the product shows that it consists of hydrated lanthanum oxycarbonate La 2 O(CO 3 ) 2 .xH 2 O, where 2 ⁇ x ⁇ 4.
- the surface area of the product was determined by the BET method. The test was repeated 3 times and slightly different surface areas and different reaction rates were obtained as shown in Table 1.
- Plasma lanthanum exposure Overall plasma lanthanum exposure in the dogs is summarized in Table 3 below. The plasma concentration curves are shown in FIG. 29 . TABLE 3 Mean (sd) Area Under the Curve 0-72 h Maximum concentration La oxycarbonate (ng ⁇ h/mL); C max (ng/mL); (standard compound tested (standard deviation) deviation) A 54.6 (28.0) 2.77 (2.1) B 42.7 (34.8) 2.45 (2.2)
- Groups of six adult Sprague-Dawley rats underwent 5 ⁇ 6th nephrectomy in two stages over a period of 2 weeks and were then allowed to recover for a further two weeks prior to being randomized for treatment.
- the groups received vehicle (0.5% w/v carboxymethyl cellulose), or lanthanum oxycarbonate A or B suspended in vehicle, once daily for 14 days by oral lavage (10 ml/kg/day). The dose delivered 314 mg elemental lanthanum/kg/day. Dosing was carried out immediately before the dark (feeding) cycle on each day.
- Urine samples 24 hours were collected prior to surgery, prior to the commencement of treatment, and twice weekly during the treatment period. Volume and phosphorus concentration were measured.
- Teklad phosphate sufficient diet (0.5% Ca, 0.3% P; Teklad No. TD85343), ad libitum.
- animals were pair fed based upon the average food consumption of the vehicle-treated animals the previous week.
- 5 ⁇ 6 Nephrectomy After one week of acclimatization, all animals were subjected to 5 ⁇ 6 nephrectomy surgery. The surgery was performed in two stages. First, the two lower branches of the left renal artery were ligated. One week later, a right nephrectomy was performed. Prior to each surgery, animals were anesthetized with an intra-peritoneal injection of ketamine/xylazine mixture (Ketaject a 100 mg/ml and Xylaject at 20 mg/ml) administered at 10 ml/kg. After each surgery, 0.25 mg/kg Buprenorphine was administered for relief of post-surgical pain. After surgery, animals were allowed to stabilize for 2 weeks to beginning treatment.
- the results showing urine phosphorus excretion are given in FIG. 30 .
- the results show a decrease in phosphorus excretion, a marker of dietary phosphorus binding, after administration of the lanthanum oxycarbonate (at time >0), compared to untreated rats.
- Test items were lanthanum oxycarbonates La 2 O 2 CO 3 and La 2 CO 5 (compound B and compound C), each tested at 0.3 and 0.6% of diet. There was an additional negative control group receiving Sigmacell cellulose in place of the test item.
- test items were mixed thoroughly into Teklad 7012CM diet. All groups received equivalent amounts of dietary nutrients.
- Table 4 outlines the dietary composition of each group: TABLE 4 Sigmacell Group ID Treatment Test Item cellulose Teklad Diet I Negative 0.0% 1.2% 98.8% control II Compound B - 0.3% 0.9% 98.8% Mid level III Compound B - 0.6% 0.6% 98.8% High level IV Compound C - 0.3% 0.9% 98.8% Mid level V Compound C - 0.6% 0.6% 98.8% High level
- Rats were maintained in the animal facility for at least five days prior to use, housed individually in stainless steel hanging cages. On the first day of testing, they were placed individually in metabolic cages along with their test diet. Every 24 hours, their output of urine and feces was measured and collected and their general health visually assessed. The study continued for 4 days. Food consumption for each day of the study was recorded. Starting and ending animal weights were recorded.
- Plasma samples were collected via retro-orbital bleeding from the control (I) and high-dose oxycarbonate groups, III and V. The rats were then euthanized with CO 2 in accordance with the IACUC study protocol.
- Urine samples were assayed for phosphorus, calcium, and creatinine concentration in a Hitachi 912 analyzer using Roche reagents. Urinary excretion of phosphorus per day was calculated for each rat from daily urine volume and phosphorus concentration. No significant changes were seen in animal weight, urine volume or creatinine excretion between groups. Food consumption was good for all groups.
- Tests were run to determine the binding efficiency of eight different compounds for twenty-four different elements. The compounds tested are given in Table 6. TABLE 6 Test ID Compound Preparation Technique 1 La 2 O 3 Calcined the commercial (Prochem) La 2 (CO 3 ) 3 .H 2 O at 850° C. for 16 hrs. 2 La 2 CO 5 Prepared by spray drying lanthanum acetate solution and calcining at 600° C. for 7 hrs (method correspond- ing to FIG. 3 ) 3 LaOCl Prepared by spray drying lanthanum chloride solution and calcining at 700° C. for 10 hrs (method corre- sponding to FIG.
- the main objective of the tests was to investigate the efficiency at which the compounds bind arsenic and selenium, in view of their use in removing those elements from drinking water. Twenty-one different anions were also included to explore further possibilities. The tests were performed as follows:
- the compounds given in Table 6 were added to water and a spike and were vigorously shaken at room temperature for 18 hrs.
- the samples were filtered and the filtrate analyzed for a suite of elements including Sb, As, Be, Cd, Ca, Cr, Co, Cu, Fe, Pb, Mg, Mn, Mo, Ni, Se, TI, Ti, V, Zn, Al, Ba, B, Ag, and P.
- the spike solution was made as follows:
- the most efficient compounds for removing both arsenic and selenium appear to be the titanium-based compounds 5 and 6.
- the lanthanum oxycarbonates made according to the process of the present invention remove at least 90% of the arsenic. Their efficiency at removing Se is in the range 70 to 80%. Commercial lanthanum carbonate (4 in Table 6) is less effective.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Geology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hydrology & Water Resources (AREA)
- Water Supply & Treatment (AREA)
- Environmental & Geological Engineering (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Water Treatment By Sorption (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Catalysts (AREA)
Abstract
Description
- The present application claims priority to U.S. Ser. No. 60/396,989 filed May 24, 2002, to U.S. Ser. No. 60/403,868 filed Aug. 14, 2002, to U.S. Ser. No. 60/430,284 filed Dec. 2, 2002, and to U.S. Ser. No. 60/461,175 filed Apr. 8, 2003, the entire contents of each is hereby incorporated by reference.
- The present invention relates to rare earth metal compounds, particularly rare earth metal compounds having a porous structure. The present invention also includes methods of making the porous rare earth metal compounds and methods of using the compounds of the present invention. The compounds of the present invention can be used to bind or absorb metals such as arsenic, selenium, antimony and metal ions such as arsenic III+ and V+. The compounds of the present invention may therefore find use in water filters or other devices or methods to remove metals and metal ions from fluids, especially water.
- The compounds of the present invention are also useful for binding or absorbing anions such as phosphate in the gastrointestinal tract of mammals. Accordingly, one use of the compounds of the present invention is to treat high serum phosphate levels in patients with end-stage renal disease undergoing kidney dialysis. In this aspect, the compounds may be provided in a filter that is fluidically connected with a kidney dialysis machine such that the phosphate content in the blood is reduced after passing through the filter.
- In another aspect, the compounds can be used to deliver a lanthanum or other rare-earth metal compound that will bind phosphate present in the gut and prevent its transfer into the bloodstream. Compounds of the present invention can also be used to deliver drugs or to act as a filter or absorber in the gastrointestinal tract or in the blood stream. For example, the materials can be used to deliver inorganic chemicals in the gastrointestinal tract or elsewhere.
- It has been found that the porous particle structure and the high surface area are beneficial to high absorption rates of anions. Advantageously, these properties permit the compounds of the present invention to be used to bind phosphate directly in a filtering device fluidically connected with kidney dialysis equipment.
- The use of rare earth hydrated oxides, particularly hydrated oxides of La, Ce, and Y to bind phosphate is disclosed in Japanese published patent application 61-004529 (1986). Similarly, U.S. Pat. No. 5,968,976 discloses a lanthanum carbonate hydrate to remove phosphate in the gastrointestinal tract and to treat hyperphosphatemia in patients with renal failure. It also shows that hydrated lanthanum carbonates with about 3 to 6 molecules of crystal water provide the highest removal rates. U.S. Pat. No. 6,322,895 discloses a form of silicon with micron-sized or nano-sized pores that can be used to release drugs slowly in the body. U.S. Pat. No. 5,782,792 discloses a method for the treatment of rheumatic arthritis where a “protein A immunoadsorbent” is placed on silica or another inert binder in a cartridge to physically remove antibodies from the bloodstream.
- It has now unexpectedly been found that the specific surface area of compounds according to the present invention as measured by the BET method, varies depending on the method of preparation, and has a significant effect on the properties of the product. As a result, the specific properties of the resulting compound can be adjusted by varying one or more parameters in the method of making the compound. In this regard, the compounds of the present invention have a BET specific surface area of at least about 10 m2/g and may have a BET specific surface area of at least about 20 m2/g and alternatively may have a BET specific surface area of at least about 35 m2 μg. In one embodiment, the compounds have a BET specific surface area within the range of about 10 m2/g and about 40 m2/g.
- It has also been found that modifications in the preparation method of the rare earth compounds will create different entities, e.g. different kinds of hydrated or amorphous oxycarbonates rather than carbonates, and that these compounds have distinct and improved properties. It has also been found that modifications of the preparation method create different porous physical structures with improved properties.
- The compounds of the present invention and in particular, the lanthanum compounds and more particularly the lanthanum oxycarbonates of the present invention exhibit phosphate binding or removal of at least 40% of the initial concentration of phosphate after ten minutes. Desirably, the lanthanum compounds exhibit phosphate binding or removal of at least 60% of the initial concentration of phosphate after ten minutes. In other words, the lanthanum compounds and in particular, the lanthanum compounds and more particularly the lanthanum oxycarbonates of the present invention exhibit a phosphate binding capacity of at least 45 mg of phosphate per gram of lanthanum compound. Suitably, the lanthanum compounds exhibit a phosphate binding capacity of at least 50 mg PO4/g of lanthanum compound, more suitably, a phosphate binding capacity of at least 75 mg PO4/g of lanthanum compound. Desirably, the lanthanum compounds exhibit a phosphate binding capacity of at least 100 mg PO4/g of lanthanum compound, more desirably, a phosphate binding capacity of at least 110 mg PO4/g of lanthanum compound.
- In accordance with the present invention, rare earth metal compounds, and in particular, rare earth metal oxychlorides and oxycarbonates are provided. The oxycarbonates may be hydrated or anhydrous. These compounds may be produced according to the present invention as particles having a porous structure. The rare earth metal compound particles of the present invention may conveniently be produced within a controllable range of surface areas with resultant variable and controllable adsorption rates of ions.
- The porous particles or porous structures of the present invention are made of nano-sized to micron-sized crystals with controllable surface areas. The rare earth oxychloride is desirably lanthanum oxychloride (LaOCl). The rare earth oxycarbonate hydrate is desirably lanthanum oxycarbonate hydrate (La2O(CO3)2.xH2O where x is from and including 2 to and including 4). This compound will further be referred to in this text as La2O(CO3)2.xH2O. The anhydrous rare earth oxycarbonate is desirably lanthanum oxycarbonate La2O2CO3 or La2CO5 of which several crystalline forms exist. The lower temperature form will be identified as La2O2CO3 and the form obtained at higher temperature or after a longer calcination time will be identified as La2CO5.
- One skilled in the art, however, will understand that lanthanum oxycarbonate may be present as a mixture of the hydrate and the anhydrous form. In addition, the anhydrous lanthanum oxycarbonate may be present as a mixture of La2O2CO3 and La2CO5 and may be present in more than a single crystalline form.
- One method of making the rare earth metal compound particles includes making a solution of rare earth metal chloride, subjecting the solution to a substantially total evaporation process using a spray dryer or other suitable equipment to form an intermediate product, and calcining the obtained intermediate product at a temperature between about 5000 and about 1200° C. The product of the calcination step may be washed, filtered, and dried to make a suitable finished product. Optionally, the intermediate product may be milled in a horizontal or vertical pressure media mill to a desired surface area and then further spray dried or dried by other means to produce a powder that may be further washed and filtered.
- An alternative method of making the rare earth metal compounds, particularly rare earth metal anhydrous oxycarbonate particles includes making a solution of rare earth metal acetate, subjecting the solution to a substantially total evaporation process using a spray dryer or other suitable equipment to make an intermediate product, and calcining the obtained intermediate product at a temperature between about 400° C. and about 700° C. The product of the calcination step may be washed, filtered, and dried to make a suitable finished product. Optionally, the intermediate product may be milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- Yet another method of making the rare earth metal compounds includes making rare earth metal oxycarbonate hydrate particles. The rare earth metal oxycarbonate hydrate particles can be made by successively making a solution of rare earth chloride, subjecting the solution to a slow, steady feed of a sodium carbonate solution at a temperature between about 30° and about 90° C. while mixing, then filtering and washing the precipitate to form a filter cake, then drying the filter cake at a temperature of about 100° to 120° C. to produce the desired rare earth oxycarbonate hydrate species. Optionally, the filter cake may be sequentially dried, slurried, and milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- Alternatively, the process for making rare earth metal oxycarbonate hydrate particles may be modified to produce anhydrous particles. This modification includes subjecting the dried filter cake to a thermal treatment at a specified temperature between about 400° C. to about 700° C. and for a specified time between 1 h and 48 h. Optionally, the product of the thermal treatment may be slurried and milled in a horizontal or vertical pressure media mill to a desired surface area, spray dried or dried by other means to produce a powder that may be washed, filtered, and dried.
- In accordance with the present invention, compounds of the present invention may be used to treat patients with hyperphosphatemia. The compounds may be made into a form that may be delivered to a mammal and that may be used to remove phosphate from the gut or decrease phosphate absorption into the blood stream. For example, the compounds may be formulated to provide an orally ingestible form such as a liquid solution or suspension, a tablet, capsule, gelcap, or other suitable and known oral form. Accordingly, the present invention contemplates a method for treating hyperphosphatemia that comprises providing an effective amount of a compound of the present invention. Compounds made under different conditions will correspond to different oxycarbonates or oxychlorides, will have different surface areas, and will show differences in reaction rates with phosphate and different solubilization of lanthanum or another rare-earth metal into the gut. The present invention allows one to modify these properties according to the requirements of the treatment.
- In another aspect of the present invention, compounds made according to this invention as a porous structure of sufficient mechanical strength may be placed in a device fluidically connected to a dialysis machine through which the blood flows, to directly remove phosphate by reaction of the rare-earth compound with phosphate in the bloodstream. The present invention therefore contemplates a device having an inlet and an outlet with one or more compounds of the present invention disposed between the inlet and the outlet. The present invention also contemplates a method of reducing the amount of phosphate in blood that comprises contacting the blood with one or more compounds of the present invention for a time sufficient to reduce the amount of phosphate in the blood.
- In yet another aspect of the present invention, the compounds of the present invention may be used as a substrate for a filter having an inlet and outlet such that the compounds of the present invention are disposed between the inlet and the outlet. A fluid containing a metal, metal ion, phosphate or other ion may be passed from the inlet to contact the compounds of the present invention and through the outlet. Accordingly, in one aspect of the present invention a method of reducing the content of a metal in a fluid, for example water, comprises flowing the fluid through a filter that contains one or more compounds of the present invention to reduce the amount of metal present in the water.
-
FIG. 1 is a general flow sheet of a process according to the present invention that produces LaOCl (lanthanum oxychloride). -
FIG. 2 is a flow sheet of a process according to the present invention that produces a coated titanium dioxide structure. -
FIG. 3 is a flow sheet of a process according to the present invention that produces lanthanum oxycarbonate -
FIG. 4 is a graph showing the percentage of phosphate removed from a solution as a function of time by LaO(CO3)2.xH2O, (where x is from and including 2 to and including 4), made according to the process of the present invention, as compared to the percentage of phosphate removed by commercial grade La carbonate La2(CO3)3.4H2O in the same conditions. -
FIG. 5 is a graph showing the amount of phosphate removed from a solution as a function of time per g of a lanthanum compound used as a drug to treat hyperphosphatemia. The drug in one case is La2O(CO3)2.xH2O (where x is from and including 2 to and including 4), made according to the process of the present invention. In the comparative case the drug is commercial grade La carbonate La2(CO3)3.4H2O. -
FIG. 6 is a graph showing the amount of phosphate removed from a solution as a function of time per g of a lanthanum compound used as a drug to treat hyperphosphatemia. The drug in one case is La2O2CO3 made according to the process of the present invention. In the comparative case the drug is commercial grade La carbonate La2(CO3)3.4H2O. -
FIG. 7 is a graph showing the percentage of phosphate removed as a function of time by La2O2CO3 made according to the process of the present invention, as compared to the percentage of phosphate removed by commercial grade La carbonate La2(CO3)3.4H2O. -
FIG. 8 is a graph showing a relationship between the specific surface area of the oxycarbonates made following the process of the present invention and the amount of phosphate bound or removed fromsolution 10 min after the addition of the oxycarbonate. -
FIG. 9 is a graph showing a linear relationship between the specific surface area of the oxycarbonates of this invention and the first order rate constant calculated from the initial rate of reaction of phosphate. -
FIG. 10 is a flow sheet of a process according to the present invention that produces lanthanum oxycarbonate hydrate La2(CO3)2.xH2O -
FIG. 11 is a flow sheet of a process according to the present invention that produces anhydrous lanthanum oxycarbonate La2O2CO3 or La2CO5. -
FIG. 12 is a scanning electron micrograph of lanthanum oxychloride, made following the process of the present invention. -
FIG. 13 is an X-Ray diffraction scan of lanthanum oxychloride LaOCl made according to the process of the present invention and compared with a standard library card of lanthanum oxychloride. -
FIG. 14 is a graph showing the percentage of phosphate removed from a solution as a function of time by LaOCl made according to the process of the present invention, as compared to the amount of phosphate removed by commercial grades of La carbonate La2(CO3)3—H2O and La2(CO3)3.4H2O in the same conditions. -
FIG. 15 shows a scanning electron micrograph of La2O(CO3)2Ox H2O, where x is from and including 2 to and including 4. -
FIG. 16 is an X-Ray diffraction scan of La2O(CO3)2.xH2O produced according to the present invention and includes a comparison with a “library standard” of La2O(CO3)2.xH2O where x is from and including 2 to and including 4. -
FIG. 17 is a graph showing the rate of removal of phosphorous from a solution by La2O(CO3)2.xH2O compared to the rate obtained with commercially available La2(CO3)3.H2O and La2(CO3)3.H2O in the same conditions. -
FIG. 18 is a scanning electron micrograph of anhydrous lanthanum oxycarbonate La2O2CO3. -
FIG. 19 is an X-Ray diffraction scan of anhydrous La2O2CO3 produced according to the present invention and includes a comparison with a “library standard” of La2O2CO3. -
FIG. 20 is a graph showing the rate of phosphorous removal obtained with La2O2CO3 made following the process of the present invention and compared to the rate obtained for commercially available La2(CO3)3.H2O and La2(CO3)3.H2O. -
FIG. 21 is a scanning electron micrograph of La2CO5 made according to the process of the present invention. -
FIG. 22 is an X-Ray diffraction scan of anhydrous La2CO5 produced according to the present invention and includes a comparison with a “library standard” of La2CO5. -
FIG. 23 is a graph showing the rate of phosphorous removal obtained with La2CO5 made following the process of the present invention and compared to the rate obtained for commercially available La2(CO3)3.H2O and La2(CO3)30.4H2O. -
FIG. 24 is a scanning electron micrograph of TiO2 support material made according to the process of the present invention. -
FIG. 25 is a scanning electron micrograph of a TiO2 structure coated with LaOCl, made according to the process of the present invention, calcined at 800° C. -
FIG. 26 is a scanning electron micrograph of a TiO2 structure coated with LaOCl, made according to the process of the present invention, calcined at 600° C. -
FIG. 27 is a scanning electron micrograph of a TiO2 structure coated with LaOCl, made according to the process of the present invention, calcined at 900° C. -
FIG. 28 . shows X-Ray scans for TiO2 coated with LaOCl and calcined at different temperatures following the process of the present invention, and compared to the X-Ray scan for pure LaOCl. -
FIG. 29 shows the concentration of lanthanum in blood plasma as a function of time, for dogs treated with lanthanum oxycarbonates made according to the process of the present invention. -
FIG. 30 shows the concentration of phosphorous in urine as a function of time in rats treated with lanthanum oxycarbonates made according to the process of the present invention, and compared to phosphorus concentration measured in untreated rats. -
FIG. 31 shows a device having an inlet, an outlet, and one or more compounds of the present invention disposed between the inlet and the outlet. - Referring now to the drawings, the process of the present invention will be described. While the description will generally refer to lanthanum compounds, the use of lanthanum is merely for ease of description and is not intended to limit the invention and claims solely to lanthanum compounds. In fact, it is contemplated that the process and the compounds described in the present specification is equally applicable to rare earth metals other than lanthanum such as Ce and Y.
- Turning now to
FIG. 1 , a process for making a rare earth oxychloride compound, and, in particular a lanthanum oxychloride compound according to one embodiment of the present invention is shown. First, a solution of lanthanum chloride is provided. The source of lanthanum chloride may be any suitable source and is not limited to any particular source. One source of lanthanum chloride solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution. Another source is to dissolve lanthanum oxide in a hydrochloric acid solution. - The lanthanum chloride solution is evaporated to form an intermediate product. The
evaporation 20 is conducted under conditions to achieve substantially total evaporation. Desirably, the evaporation is conducted at a temperature higher than the boiling point of the feed solution (lanthanum chloride) but lower than the temperature where significant crystal growth occurs. The resulting intermediate product may be an amorphous solid formed as a thin film or may have a spherical shape or a shape as part of a sphere. - The terms “substantially total evaporation” or “substantially complete evaporation” as used in the specification and claims refer to evaporation such that the resulting solid intermediate contains less than 15% free water, desirably less than 10% free water, and more desirably less than 1% free water. The term “free water” is understood and means water that is not chemically bound and can be removed by heating at a temperature below 150° C. After substantially total evaporation or substantially complete evaporation, the intermediate product will have no visible moisture present.
- The evaporation step may be conducted in a spray dryer. In this case, the intermediate product will consist of a structure of spheres or parts of spheres. The spray dryer generally operates at a discharge temperature between about 120° C. and about 500° C.
- The intermediate product may then be calcined in any
suitable calcination apparatus 30 by raising the temperature to a temperature between about 500° C. to about 1200° C. for a period of time from about 2 to about 24 h and then cooling to room temperature. The cooled product may be washed 40 by immersing it in water or dilute acid, to remove any water-soluble phase that may still be present after thecalcination step 30. - The temperature and the length of time of the calcination process may be varied to adjust the particle size and the reactivity of the product. The particles resulting from calcination generally have a size between 1 and 1000 μm. The calcined particles consist of individual crystals, bound together in a structure with good physical strength and a porous structure. The individual crystals forming the particles generally have a size between 20 nm and 10 μm.
- In accordance with another embodiment of the present invention as shown in
FIG. 2 , a feed solution of titanium chloride or titanium oxychloride is provided by any suitable source. One source is to dissolve anhydrous titanium chloride in water or in a hydrochloric acid solution. Chemical control agents oradditives 104 may be introduced to this feed solution to influence the crystal form and the particle size of the final product. One chemical additive is sodium phosphate Na3PO4. The feed solution of titanium chloride or titanium oxychloride is mixed with the optionalchemical control agent 104 in asuitable mixing step 110. The mixing may be conducted using any suitable known mixer. - The feed solution is evaporated to form an intermediate product, which in this instance is titanium dioxide (TiO2). The
evaporation 120 is conducted at a temperature higher than the boiling point of the feed solution but lower than the temperature where significant crystal growth occurs and to achieve substantially total evaporation. The resulting intermediate product may desirably be an amorphous solid formed as a thin film and may have a spherical shape or a shape as part of a sphere. - The intermediate product may then be calcined in any
suitable calcination apparatus 130 by raising the temperature to a temperature between about 400° C. to about 1200° C. for a period of time from about 2 to about 24 h and then cooling to room temperature (25° C.). The cooled product is then washed 140 by immersing it in water or dilute acid, to remove traces of any water-soluble phase that may still be present after the calcination step. - The method of manufacture of the intermediate product according to the present invention can be adjusted and chosen to make a structure with the required particle size and porosity. For example, the
evaporation step 120 and thecalcination step 130 can be adjusted for this purpose. The particle size and porosity can be adjusted to make the structure of the intermediate product suitable to be used as an inert filter in the bloodstream. - The washed TiO2 product is then suspended or slurried in a solution of an inorganic compound. A desirable inorganic compound is a rare-earth or lanthanum compound, and in particular lanthanum chloride. This suspension of TiO2 in the inorganic compound solution is again subjected to
total evaporation 160 under conditions in the same range as defined instep 120 and to achieve substantially total evaporation. In this regard, the evaporation steps 120 and 160 may be conducted in a spray drier. The inorganic compound will precipitate as a salt, an oxide, or an oxy-salt. If the inorganic compound is lanthanum chloride, the precipitated product will be lanthanum oxychloride. If the original compound is lanthanum acetate, the precipitated product will be lanthanum oxide. - The product of
step 160 is further calcined 170 at a temperature between 500° and 1100° C. for a period of 2 to 24 h. The temperature and the time of the calcination process influence the properties and the particle size of the product. After thesecond calcination step 170, the product may be washed 180. - The resulting product can be described as crystals of lanthanum oxychloride or lanthanum oxide formed on a TiO2 substrate. The resulting product may be in the form of hollow thin-film spheres or parts of spheres. The spheres will have a size of about 1 μm to 1000 μm and will consist of a structure of individual bound particles. The individual particles have a size between 20 nm and 10 μm.
- When the final product consists of crystals of lanthanum oxychloride on a TiO2 substrate, these crystals may be hydrated. It has been found that this product will effectively react with phosphate and bind it as an insoluble compound. It is believed that, if this final product is released in the human stomach and gastrointestinal tract, the product will bind the phosphate that is present and decrease the transfer of phosphate from the stomach and gastrointestinal tract to the blood stream. Therefore, the product of this invention may be used to limit the phosphorous content in the bloodstream of patients on kidney dialysis.
- According to another embodiment of the present invention, a process for making anhydrous lanthanum oxycarbonate is shown in
FIG. 3 . In this process, a solution of lanthanum acetate is made by any method. One method to make the lanthanum acetate solution is to dissolve commercial lanthanum acetate crystals in water or in an HCl solution. - The lanthanum acetate solution is evaporated to form an intermediate product. The
evaporation 220 is conducted at a temperature higher than the boiling point of the lanthanum acetate solution but lower than the temperature where significant crystal growth occurs and under conditions to achieve substantially total evaporation. The resulting intermediate product may desirably be an amorphous solid formed as a thin film and may have a spherical shape or a shape as part of a sphere. - The intermediate product may then be calcined in any
suitable calcination apparatus 230 by raising the temperature to a temperature between about 400° C. to about 800° C. for a period of time from about 2 to about 24 h and then cooled to room temperature. The cooled product may be washed 240 by immersing it in water or dilute acid, to remove any water-soluble phase that may still be present after the calcination step. The temperature and the length of time of the calcination process may be varied to adjust the particle size and the reactivity of the product. - The particles resulting from the calcination generally have a size between 1 and 1000 μm. The calcined particles consist of individual crystals, bound together in a structure with good physical strength and a porous structure. The individual crystals generally have a size between 20 nm and 10 μm.
- The products made by methods shown in
FIGS. 1, 2 , and 3 comprise ceramic particles with a porous structure. Individual particles are in the micron size range. The particles are composed of crystallites in the nano-size range, fused together to create a structure with good strength and porosity. - The particles made according to the process of the present invention, have the following common properties:
-
- a. They have low solubility in aqueous solutions, especially serum and gastro-intestinal fluid, compared to non-ceramic compounds.
- b. Their hollow shape gives them a low bulk density compared to solid particles. Lower density particles are less likely to cause retention in the gastro-intestinal tract.
- c. They have good phosphate binding kinetics. The observed kinetics are generally better than the commercial carbonate hydrates La2(CO3)3—H2O and La2(CO3)3.4H2O. In the case of lanthanum oxychloride, the relationship between the amount of phosphate bound or absorbed and time tends to be closer to linear than for commercial hydrated lanthanum carbonates. The initial reaction rate is lower but does not significantly decrease with time over an extended period. This behavior is defined as linear or substantially linear binding kinetics. This is probably an indication of more selective phosphate binding in the presence of other anions.
- d. Properties a, b, and c, above are expected to lead to less gastro-intestinal tract complications than existing products.
- e. Because of their particular structure and low solubility, the products of the present invention have the potential to be used in a filtration device placed directly in the bloodstream.
- Different lanthanum oxycarbonates have been prepared by different methods. It has been found that, depending on the method of preparation, lanthanum oxycarbonate compounds with widely different reaction rates are obtained.
- A desirable lanthanum oxycarbonate is La2O(CO3)2.xH2O, where 2≦x≦4. This lanthanum oxycarbonate is preferred because it exhibits a relatively high rate of removal of phosphate. To determine the reactivity of the lanthanum oxycarbonate compound with respect to phosphate, the following procedure was used. A stock solution containing 13.75 g/l of anhydrous Na2HPO4 and 8.5 g/l of HCl is prepared. The stock solution is adjusted to pH 3 by the addition of concentrated HCl. 100 ml of the stock solution is placed in a beaker with a stirring bar. A sample of lanthanum oxycarbonate powder is added to the solution. The amount of lanthanum oxycarbonate powder is such that the amount of La in suspension is 3 times the stoichiometric amount needed to react completely with the phosphate. Samples of the suspension are taken at intervals, through a filter that separated all solids from the liquid. The liquid sample is analyzed for phosphorous.
FIG. 4 shows that after 10 min, La2O(CO3)2.xH2O has removed 86% of the phosphate in solution, whereas a commercial hydrated La carbonate La2(CO3)3.H2O removes only 38% of the phosphate in the same experimental conditions after the same time. -
FIG. 5 shows that the La2O(CO3)2.xH2O depicted inFIG. 4 has a capacity of phosphate removal of 110 mg PO4 removed/g of La compound after 10 min in the conditions described above, compared to 45 mg PO4/g for the commercial La carbonate taken as reference. - Another preferred lanthanum carbonate is the anhydrous La oxycarbonate La2O2CO3. This compound is preferred because of its particularly high binding capacity for phosphate, expressed as mg PO4 removed/g of compound.
FIG. 6 shows that La2O2CO3 binds 120 mg PO4/g of La compound after 10 min, whereas La2(CO3)3.4H2O used as reference only binds 45 mg PO4/g La compound. -
FIG. 7 shows the rate of reaction with phosphate of the oxycarbonate La2O2CO3. After 10 min of reaction, 73% of the phosphate had been removed, compared to 38% for commercial lanthanum carbonate used as reference. - Samples of different oxycarbonates have been made by different methods as shown in Table 1 below.
TABLE 1 Initial Example number BET Fraction of 1st order corresponding to surface PO4 rate constant manufacturing area remaining k1 Sample Compound method m2/g after 10 min (min−1) 1 La2O(CO3)2.xH2O 11 41.3 0.130 0.949 2 La2O(CO3)2.xH2O 11 35.9 0.153 0.929 3 La2O(CO3)2.xH2O 11 38.8 0.171 0.837 4 La2CO5 (4 h milling) 7 25.6 0.275 0.545 5 La2O2CO3 5 18 0.278 0.483 6 La2CO5 (2 h milling) 7 18.8 0.308 0.391 7 La2O2CO3 7 16.5 0.327 0.36 8 La2CO5 (no milling) 5 11.9 0.483 0.434 9 La2(CO3)3.4H2O commercial 4.3 0.623 0.196 sample 10 La2(CO3)3.1H2O commercial 2.9 0.790 0.094 sample - For each sample, the surface area measured by the BET method and the fraction of phosphate remaining after 10 min of reaction have been tabulated. The table also shows the rate constant k1 corresponding to the initial rate of reaction of phosphate, assuming the reaction is first order in phosphate concentration. The rate constant k1 is defined by the following equation:
d[PO4 ]/dt=−k 1[PO4]
where [PO4] is the phosphate concentration in solution (mol/liter), t is time (min) and k1 is the first order rate constant (min−1). The table gives the rate constant for the initial reaction rate, i.e. the rate constant calculated from the experimental points for the first minute of the reaction. -
FIG. 8 shows that there is a good correlation between the specific surface area and the amount of phosphate reacted after 10 min. It appears that in this series of tests, the most important factor influencing the rate of reaction is the surface area, independently of the composition of the oxycarbonate or the method of manufacture. A high surface area can be achieved by adjusting the manufacturing method or by milling a manufactured product. -
FIG. 9 shows that a good correlation is obtained for the same compounds by plotting the first order rate constant as given in Table I and the BET specific surface area. The correlation can be represented by a straight line going through the origin. In other words, within experimental error, the initial rate of reaction appears to be proportional to the phosphate concentration and also to the available surface area. - Without being bound by any theory, it is proposed that the observed dependence on surface area and phosphate concentration may be explained by a nucleophilic attack of the phosphate ion on the La atom in the oxycarbonate, with resultant formation of lanthanum phosphate LaPO4. For example, if the oxycarbonate is La2O2CO3, the reaction will be:
½ La2O2CO3+PO4 3−+2H2O→LaPO4+½ H2CO3+3OH−
If the rate is limited by the diffusion of the PO4 3− ion to the surface of the oxycarbonate and the available area of oxycarbonate, the observed relationship expressed inFIG. 9 can be explained. This mechanism does not require La to be present as a dissolved species. The present reasoning also provides an explanation for the decrease of the reaction rate after the first minutes: the formation of lanthanum phosphate on the surface of the oxycarbonate decreases the area available for reaction. - In general, data obtained at increasing pH show a decrease of the reaction rate. This may be explained by the decrease in concentration of the hydronium ion (H3O+), which may catalyze the reaction by facilitating the formation of the carbonic acid molecule from the oxycarbonate.
- Turning now to
FIG. 10 , another process for making lanthanum oxycarbonate and in particular, lanthanum oxycarbonate tetra hydrate, is shown. First, an aqueous solution of lanthanum chloride is made by any method. One method to make the solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution. Another method to make the lanthanum chloride solution is to dissolve lanthanum oxide in a hydrochloric acid solution. - The LaCl3 solution is placed in a well-stirred tank reactor. The LaCl3 solution is then heated to 80° C. A previously prepared analytical grade sodium carbonate is steadily added over a period of 2 hours with vigorous mixing. The mass of sodium carbonate required is calculated at 6 moles of sodium carbonate per 2 moles of LaCl3. When the required mass of sodium carbonate solution is added, the resultant slurry or suspension is allowed to cure for 2 hours at 80° C. The suspension is then filtered and washed with demineralized water to produce a clear filtrate. The filter cake is placed in a convection oven at 105° C. for 2 hours or until a stable weight is observed. The initial pH of the LaCl3 solution is 2, while the final pH of the suspension after cure is 5.5. A white powder is produced. The resultant powder is a lanthanum oxycarbonate four hydrate (La2O(CO3)2.xH2O). The number of water molecules in this compound is approximate and may vary between 2 and 4 (and including 2 and 4).
- Turning now to
FIG. 11 another process for making anhydrous lanthanum oxycarbonate is shown. First, an aqueous solution of lanthanum chloride is made by any method. One method to make the solution is to dissolve commercial lanthanum chloride crystals in water or in an HCl solution. Another method to make the lanthanum chloride solution is to dissolve lanthanum oxide in a hydrochloric acid solution. - The LaCl3 solution is placed in a well-stirred tank reactor. The LaCl3 solution is then heated to 80° C. A previously prepared analytical grade sodium carbonate is steadily added over 2 hours with vigorous mixing. The mass of sodium carbonate required is calculated at 6 moles of sodium carbonate per 2 moles of LaCl3. When the required mass of sodium carbonate solution is added the resultant slurry or suspension is allowed to cure for 2 hours at 80° C. The suspension is then washed and filtered removing NaCl (a byproduct of the reaction) to produce a clear filtrate. The filter cake is placed in a convection oven at 105° C. for 2 hours or until a stable weight is observed. The initial pH of the LaCl3 solution is 2.2, while the final pH of the suspension after cure is 5.5. A white lanthanum oxycarbonate hydrate powder is produced. Next the lanthanum oxycarbonate hydrate is placed in an alumina tray, which is placed in a high temperature muffle furnace. The white powder is heated to 500° C. and held at that temperature for 3 hours. Anhydrous La2C2O3 is formed.
- Alternatively, the anhydrous lanthanum oxycarbonate formed as indicated in the previous paragraph may be heated at 500° C. for 15 to 24 h instead of 3 h or at 600° C. instead of 500° C. The resulting product has the same chemical formula, but shows a different pattern in an X-Ray diffraction scan and exhibits a higher physical strength and a lower surface area. The product corresponding to a higher temperature or a longer calcination time is defined here as La2CO5.
- Turning now to
FIG. 31 , adevice 500 having an inlet 502 and an outlet 504 is shown. Thedevice 500 may be in the form of a filter or other suitable container. Disposed between the inlet 502 and the outlet 504 is asubstrate 506 in the form of a plurality of one or more compounds of the present invention. The device may be fluidically connected to a dialysis machine through which the blood flows, to directly remove phosphate by reaction of the rare-earth compound with phosphate in the bloodstream. In this connection, the present invention also contemplates a method of reducing the amount of phosphate in blood that comprises contacting the blood with one or more compounds of the present invention for a time sufficient to reduce the amount of phosphate in the blood. - In yet another aspect of the present invention, the
device 500 may be provided in a fluid stream so that a fluid containing a metal, metal ion, phosphate or other ion may be passed from the inlet 502 through thesubstrate 506 to contact the compounds of the present invention and out the outlet 504. Accordingly, in one aspect of the present invention a method of reducing the content of a metal in a fluid, for example water, comprises flowing the fluid through adevice 500 that contains one or more compounds of the present invention to reduce the amount of metal present in the water. - The following examples are meant to illustrate but not limit the present invention.
- An aqueous solution containing 100 g/l of La as lanthanum chloride is injected in a spray dryer with an outlet temperature of 250° C. The intermediate product corresponding to the spray-drying step is recovered in a bag filter. This intermediate product is calcined at 900° C. for 4 hours.
FIG. 12 shows a scanning electron micrograph of the product, enlarged 25,000 times. The micrograph shows a porous structure formed of needle-like particles. The X-Ray diffraction pattern of the product (FIG. 13 ) shows that it consists of lanthanum oxychloride LaOCl. - To determine the reactivity of the lanthanum compound with respect to phosphate, the following test was conducted. A stock solution containing 13.75 g/l of anhydrous Na2HPO4 and 8.5 g/l of HCl was prepared. The stock solution was adjusted to pH 3 by the addition of concentrated HCl. An amount of 100 ml of the stock solution was placed in a beaker with a stirring bar. The lanthanum oxychloride from above was added to the solution to form a suspension. The amount of lanthanum oxychloride was such that the amount of La in suspension was 3 times the stoichiometric amount needed to react completely with the phosphate. Samples of the suspension were taken at time intervals, through a filter that separated all solids from the liquid. The liquid sample was analyzed for phosphorous.
FIG. 14 shows the rate of phosphate removed from solution. - To determine the reactivity of a commercial lanthanum with respect to phosphate, the relevant portion of Example 1 was repeated under the same conditions, except that commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O was used instead of the lanthanum oxychloride of the present invention. Additional curves on
FIG. 14 show the rate of removal of phosphate corresponding to commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3).4H2O.FIG. 14 shows that the rate of removal of phosphate with the commercial lanthanum carbonate is faster at the beginning but slower after about 3 minutes. - An aqueous HCl solution having a volume of 334.75 ml and containing LaCl3 (lanthanum chloride) at a concentration of 29.2 wt % as La2O3 was added to a four liter beaker and heated to 80° C. with stirring. The initial pH of the LaCl3 solution was 2.2. Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na2CO3) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper, the filtrate was separated from the white powder product. The filter cake was mixed four times with 2 liters of distilled water and filtered to wash away the NaCl formed during the reaction. The washed filter cake was placed into a convection oven set at 105° C. for 2 hours, or until a stable weight was observed.
FIG. 15 shows a scanning electron micrograph of the product, enlarged 120,000 times. The micrograph shows the needle-like structure of the compound. The X-Ray diffraction pattern of the product (FIG. 16 ) shows that it consists of hydrated lanthanum oxycarbonate hydrate (La2O(CO3)2.xH2O), with 2≦x≦4. - To determine the reactivity of the lanthanum compound with respect to phosphate, the following test was conducted. A stock solution containing 13.75 g/l of anhydrous Na2HPO4 and 8.5 g/l of HCl was prepared. The stock solution was adjusted to pH 3 by the addition of concentrated HCl. An amount of 100 ml of the stock solution was placed in a beaker with a stirring bar. Lanthanum oxycarbonate hydrate powder made as described above was added to the solution. The amount of lanthanum oxycarbonate hydrate powder was such that the amount of La in suspension was 3 times the stoichiometric amount needed to react completely with the phosphate. Samples of the suspension were taken at time intervals through a filter that separated all solids from the liquid. The liquid sample was analyzed for phosphorous.
FIG. 17 shows the rate of phosphate removed from solution. - To determine the reactivity of a commercial lanthanum with respect to phosphate, the second part of Example 3 was repeated under the same conditions, except that commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O was used instead of the lanthanum oxychloride of the present invention.
FIG. 17 shows the rate of phosphate removed using the commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O.FIG. 17 shows that the rate of removal of phosphate with the lanthanum oxycarbonate is faster than with the commercial lanthanum carbonate hydrate (La2(CO3)3.H2O and La2(CO3)3.4H2O). - An aqueous HCl solution having a volume of 334.75 ml and containing LaCl3 (lanthanum chloride) at a concentration of 29.2 wt % as La2O3 was added to a 4 liter beaker and heated to 80° C. with stirring. The initial pH of the LaCl3 solution was 2.2. Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na2CO3) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper the filtrate was separated from the white powder product. The filter cake was mixed four times with 2 liters of distilled water and filtered to wash away the NaCl formed during the reaction. The washed filter cake was placed into a convection oven set at 105° C. for 2 hours until a stable weight was observed. Finally, the lanthanum oxycarbonate was placed in an alumina tray in a muffle furnace. The furnace temperature was ramped to 500° C. and held at that temperature for 3 hours. The resultant product was determined to be anhydrous lanthanum oxycarbonate La2O2CO3.
- The process was repeated three times. In one case, the surface area of the white powder was determined to be 26.95 m2/gm. In the other two instances, the surface area and reaction rate is shown in Table 1.
FIG. 18 is a scanning electron micrograph of the structure, enlarged 60,000 times. The micrograph shows that the structure in this compound is made of equidimensional or approximately round particles of about 100 nm in size.FIG. 19 is an X-ray diffraction pattern showing that the product made here is an anhydrous lanthanum oxycarbonate written as La2O2CO3. - To determine the reactivity of this lanthanum compound with respect to phosphate, the following test was conducted. A stock solution containing 13.75 g/l of anhydrous Na2HPO4 and 8.5 g/l of HCl was prepared. The stock solution was adjusted to pH 3 by the addition of concentrated HCl. An amount of 100 ml of the stock solution was placed in a beaker with a stirring bar. Anhydrous lanthanum oxycarbonate made as described above, was added to the solution. The amount of anhydrous lanthanum oxycarbonate was such that the amount of La in suspension was 3 times the stoichiometric amount needed to react completely with the phosphate. Samples of the suspension were taken at intervals, through a filter that separated all solids from the liquid. The liquid sample was analyzed for phosphorous.
FIG. 20 shows the rate of phosphate removed. - To determine the reactivity of a commercial lanthanum with respect to phosphate, the second part of Example 5 was repeated under the same conditions, except that commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O was used instead of the La2O2CO3 of the present invention.
FIG. 20 shows the rate of removal of phosphate using the commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O.FIG. 20 shows that the rate of removal of phosphate with the anhydrous lanthanum oxycarbonate produced according to the process of the present invention is faster than the rate observed with commercial lanthanum carbonate hydrate La2(CO3)3.H2O and La2(CO3)3.4H2O. - A solution containing 100 g/l of La as lanthanum acetate is injected in a spray-drier with an outlet temperature of 250° C. The intermediate product corresponding to the spray-drying step is recovered in a bag filter. This intermediate product is calcined at 600° C. for 4 hours.
FIG. 21 shows a scanning electron micrograph of the product, enlarged 80,000 times.FIG. 22 shows the X-Ray diffraction pattern of the product and it shows that it consists of anhydrous lanthanum oxycarbonate. The X-Ray pattern is different from the pattern corresponding to Example 5, even though the chemical composition of the compound is the same. The formula for this compound is written as (La2CO5). ComparingFIGS. 21 and 18 shows that the compound of the present example shows a structure of leaves and needles as opposed to the round particles formed in Example 5. The particles may be used in a device to directly remove phosphate from an aqueous or non-aqueous medium, e.g., the gut or the bloodstream. - To determine the reactivity of the lanthanum compound with respect to phosphate, the following test was conducted. A stock solution containing 13.75 g/l of anhydrous Na2HPO4 and 8.5 g/l of HCl was prepared. The stock solution was adjusted to pH 3 by the addition of concentrated HCl. An amount of 100 ml of the stock solution was placed in a beaker with a stirring bar. La2CO5 powder, made as described above, was added to the solution. The amount of lanthanum oxycarbonate was such that the amount of La in suspension was 3 times the stoichiometric amount needed to react completely with the phosphate. Samples of the suspension were taken at intervals through a filter that separated all solids from the liquid. The liquid sample was analyzed for phosphorous.
FIG. 23 shows the rate of phosphate removed from solution. - To determine the reactivity of a commercial lanthanum with respect to phosphate commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O was used instead of the lanthanum oxycarbonate made according to the present invention as described above.
FIG. 23 shows the rate of phosphate removal for the commercial lanthanum carbonate La2(CO3)3.H2O and La2(CO3)3.4H2O.FIG. 23 also shows that the rate of phosphate removal with the lanthanum oxycarbonate is faster than the rate of phosphate removal with commercial lanthanum carbonate hydrate La2(CO3)3.H2O and La2(CO3)3.4H2O. - To a solution of titanium chloride or oxychloride containing 120 g/l Ti and 450 g/l Cl is added the equivalent of 2.2 g/l of sodium phosphate Na3PO4. The solution is injected in a spray dryer with an outlet temperature of 250° C. The spray dryer product is calcined at 1050° C. for 4 h. The product is subjected to two washing steps in 2 molar HCl and to two washing steps in water.
FIG. 24 is a scanning electron micrograph of the TiO2 material obtained. It shows a porous structure with individual particles of about 250 nm connected in a structure. This structure shows good mechanical strength. This material can be used as an inert filtering material in a fluid stream such as blood. - The product of Example 9 is re-slurried into a solution of lanthanum chloride containing 100 g/l La. The slurry contains approximately 30% TiO2 by weight. The slurry is spray dried in a spray dryer with an outlet temperature of 250° C. The product of the spray drier is further calcined at 800° C. for 5 h. It consists of a porous TiO2 structure with a coating of nano-sized lanthanum oxychloride.
FIG. 25 is a scanning electron micrograph of this coated product. The electron micrograph shows that the TiO2 particles are several microns in size. The LaOCl is present as a crystallized deposit with elongated crystals, often about 1 μm long and 0.1 μm across, firmly attached to the TiO2 catalyst support surface as a film of nano-size thickness. The LaOCl growth is controlled by the TiO2 catalyst support structure. Orientation of rutile crystals works as a template for LaOCl crystal growth. The particle size of the deposit can be varied from the nanometer to the micron range by varying the temperature of the second calcination step. -
FIG. 26 is a scanning electron micrograph corresponding to calcination at 600° C. instead of 800° C. It shows LaOCl particles that are smaller and less well attached to the TiO2 substrate.FIG. 27 is a scanning electron micrograph corresponding to calcination at 900° C. instead of 800° C. The product is similar to the product made at 800° C., but the LaOCl deposit is present as somewhat larger crystals and more compact layer coating the TiO2 support crystals.FIG. 28 shows the X-Ray diffraction patterns corresponding to calcinations at 600°, 800° and 900° C. The figure also shows the pattern corresponding to pure LaOCl. The peaks that do not appear in the pure LaOCl pattern correspond to rutile TiO2. As the temperature increases, the peaks tend to become higher and narrower, showing that the crystal size of the LaOCl as well as TiO2 increases with the temperature. - An aqueous HCl solution having a volume of 334.75 ml and containing LaCl3 (lanthanum chloride) at a concentration of 29.2 wt % as La2O3 was added to a 4 liter beaker and heated to 80° C. with stirring. The initial pH of the LaCl3 solution was 2.2. Two hundred and sixty five ml of an aqueous solution containing 63.59 g of sodium carbonate (Na2CO3) was metered into the heated beaker using a small pump at a steady flow rate for 2 hours. Using a Buchner filtering apparatus fitted with filter paper the filtrate was separated from the white powder product. The filter cake was mixed four times, each with 2 liters of distilled water and filtered to wash away the NaCl formed during the reaction. The washed filter cake was placed into a convection oven set at 105° C. for 2 hours or until a stable weight was observed. The X-Ray diffraction pattern of the product shows that it consists of hydrated lanthanum oxycarbonate La2O(CO3)2.xH2O, where 2≦x≦4. The surface area of the product was determined by the BET method. The test was repeated 3 times and slightly different surface areas and different reaction rates were obtained as shown in Table 1.
- Six adult beagle dogs were dosed orally with capsules of lanthanum oxycarbonate La2O(CO3)2.xH2O (compound A) or La2O2CO3 (compound B) in a cross-over design using a dose of 2250 mg elemental lanthanum twice daily (6 hours apart). The doses were administered 30 minutes after provision of food to the animals. At least 14 days washout was allowed between the crossover arms. Plasma was obtained pre-dose and 1.5, 3, 6, 7.5, 9, 12, 24, 36, 48, 60, and 72 hours after dosing and analyzed for lanthanum using ICP-MS. Urine was collected by catheterization before and approximately 24 hours after dosing and creatinine and phosphorus concentrations measured.
- The tests led to reduction of urine phosphate excretion, a marker of phosphorous binding. Values of phosphate excretion in urine are shown in Table 2 below.
TABLE 2 Median phosphorus/ creatinine ratio (% La Oxycarbonate reduction compared 10th and 90th compound to pre-dose value) percentiles A 48.4% 22.6-84.4% B 37.0% −4.1-63.1% - Plasma lanthanum exposure: Overall plasma lanthanum exposure in the dogs is summarized in Table 3 below. The plasma concentration curves are shown in
FIG. 29 .TABLE 3 Mean (sd) Area Under the Curve0-72 h Maximum concentration La oxycarbonate (ng · h/mL); Cmax (ng/mL); (standard compound tested (standard deviation) deviation) A 54.6 (28.0) 2.77 (2.1) B 42.7 (34.8) 2.45 (2.2) - Groups of six adult Sprague-Dawley rats underwent ⅚th nephrectomy in two stages over a period of 2 weeks and were then allowed to recover for a further two weeks prior to being randomized for treatment. The groups received vehicle (0.5% w/v carboxymethyl cellulose), or lanthanum oxycarbonate A or B suspended in vehicle, once daily for 14 days by oral lavage (10 ml/kg/day). The dose delivered 314 mg elemental lanthanum/kg/day. Dosing was carried out immediately before the dark (feeding) cycle on each day. Urine samples (24 hours) were collected prior to surgery, prior to the commencement of treatment, and twice weekly during the treatment period. Volume and phosphorus concentration were measured.
- Feeding—During the acclimatization and surgery period, the animals were given Teklad phosphate sufficient diet (0.5% Ca, 0.3% P; Teklad No. TD85343), ad libitum. At the beginning of the treatment period, animals were pair fed based upon the average food consumption of the vehicle-treated animals the previous week.
- ⅚ Nephrectomy—After one week of acclimatization, all animals were subjected to ⅚ nephrectomy surgery. The surgery was performed in two stages. First, the two lower branches of the left renal artery were ligated. One week later, a right nephrectomy was performed. Prior to each surgery, animals were anesthetized with an intra-peritoneal injection of ketamine/xylazine mixture (Ketaject a 100 mg/ml and Xylaject at 20 mg/ml) administered at 10 ml/kg. After each surgery, 0.25 mg/kg Buprenorphine was administered for relief of post-surgical pain. After surgery, animals were allowed to stabilize for 2 weeks to beginning treatment.
- The results showing urine phosphorus excretion are given in
FIG. 30 . The results show a decrease in phosphorus excretion, a marker of dietary phosphorus binding, after administration of the lanthanum oxycarbonate (at time >0), compared to untreated rats. - Six young adult male Sprague-Dawley rats were randomly assigned to each group. Test items were lanthanum oxycarbonates La2O2CO3 and La2CO5 (compound B and compound C), each tested at 0.3 and 0.6% of diet. There was an additional negative control group receiving Sigmacell cellulose in place of the test item.
- The test items were mixed thoroughly into Teklad 7012CM diet. All groups received equivalent amounts of dietary nutrients.
- Table 4 outlines the dietary composition of each group:
TABLE 4 Sigmacell Group ID Treatment Test Item cellulose Teklad Diet I Negative 0.0% 1.2% 98.8% control II Compound B - 0.3% 0.9% 98.8% Mid level III Compound B - 0.6% 0.6% 98.8% High level IV Compound C - 0.3% 0.9% 98.8% Mid level V Compound C - 0.6% 0.6% 98.8% High level - Rats were maintained in the animal facility for at least five days prior to use, housed individually in stainless steel hanging cages. On the first day of testing, they were placed individually in metabolic cages along with their test diet. Every 24 hours, their output of urine and feces was measured and collected and their general health visually assessed. The study continued for 4 days. Food consumption for each day of the study was recorded. Starting and ending animal weights were recorded.
- Plasma samples were collected via retro-orbital bleeding from the control (I) and high-dose oxycarbonate groups, III and V. The rats were then euthanized with CO2 in accordance with the IACUC study protocol.
- Urine samples were assayed for phosphorus, calcium, and creatinine concentration in a Hitachi 912 analyzer using Roche reagents. Urinary excretion of phosphorus per day was calculated for each rat from daily urine volume and phosphorus concentration. No significant changes were seen in animal weight, urine volume or creatinine excretion between groups. Food consumption was good for all groups.
- Even though lanthanum dosage was relatively low compared to the amount of phosphate in the diet, phosphate excretion for 0.3 or 0.6% La added to the diet decreased as shown in Table 5 below. Table 5 shows average levels of urinary phosphate over
days TABLE 5 Urinary phosphate excretion (mg/day) Control 4.3 Compound B = La2O2CO3 2.3 Compound C = La2CO5 1.9 - Tests were run to determine the binding efficiency of eight different compounds for twenty-four different elements. The compounds tested are given in Table 6.
TABLE 6 Test ID Compound Preparation Technique 1 La2O3 Calcined the commercial (Prochem) La2(CO3)3.H2O at 850° C. for 16 hrs. 2 La2CO5 Prepared by spray drying lanthanum acetate solution and calcining at 600° C. for 7 hrs (method correspond- ing to FIG. 3 )3 LaOCl Prepared by spray drying lanthanum chloride solution and calcining at 700° C. for 10 hrs (method corre- sponding to FIG. 1 )4 La2(CO3)3.4H2O Purchased from Prochem (comparative example) 5 Ti carbonate Made by the method of FIG. 11 , wherethe LaCl3 solution is replaced by a TiOCl2 solution. 6 TiO2 Made by the method corresponding to FIG. 2 , with addition of sodiumchloride. 7 La2O(CO3)2.xH2O Precipitation by adding sodium carbonate solution to lanthanum chloride solution at 80° C. (Method corresponding of FIG. 10 )8 La2O2CO3 Precipitation by adding sodium carbonate solution to lanthanum chloride solution at 80° C. followed by calcination at 500° C. for 3 hrs. (Method of FIG. 11 ) - The main objective of the tests was to investigate the efficiency at which the compounds bind arsenic and selenium, in view of their use in removing those elements from drinking water. Twenty-one different anions were also included to explore further possibilities. The tests were performed as follows:
- The compounds given in Table 6 were added to water and a spike and were vigorously shaken at room temperature for 18 hrs. The samples were filtered and the filtrate analyzed for a suite of elements including Sb, As, Be, Cd, Ca, Cr, Co, Cu, Fe, Pb, Mg, Mn, Mo, Ni, Se, TI, Ti, V, Zn, Al, Ba, B, Ag, and P.
- The spike solution was made as follows:
-
- 1. In a 500 ml volumetric cylinder add 400 ml of de-ionized water.
- 2. Add standard solutions of the elements given above to make solutions containing approximately 1 mg/l of each element.
- 3. Dilute to 500 mls with de-ionized water.
- The tests were conducted as follows:
-
- 1. Weigh 0.50 g of each compound into its own 50 ml centrifuge tube.
- 2. Add 30.0 ml of the spike solution to each.
- 3. Cap tightly and shake vigorously for 18 hrs.
- 4. Filter solution from each centrifuge tube through 0.2 μm syringe filter. Obtain ˜6 ml of filtrate.
- 5. Dilute filtrates 5:10 with 2% HNO3. Final Matrix is 1% HNO3.
- 6. Submit for analysis.
- The results of the tests are given in Table 7.
TABLE 7 % of the Analyte Removed Sb As Be Cd Ca Cr Co Cu Fe Pb Mg Mn La2O3 89 85 97 95 21 100 69 89 92 92 0 94 La2CO5 96 93 100 83 0 100 52 97 100 99 0 99 LaOCl 86 76 89 46 0 100 28 88 100 99 0 28 La2(CO3)3.4H2O 84 25 41 37 28 94 20 0 56 90 0 20 Ti(CO3)2 96 93 100 100 99 99 99 98 100 98 79 100 TiO2 96 93 8 4 0 6 0 11 49 97 0 1 La2O(CO3)2.xH2O 87 29 53 37 28 100 20 10 58 98 0 25 La2O2CO3 97 92 100 85 21 100 59 98 100 99 0 99 % of the Analyte Removed Mo Ni Se Tl Ti V Zn Al Ba B Ag P La2O3 89 28 72 8 90 95 95 85 23 0 47 96 La2CO5 98 17 79 8 100 99 100 93 0 0 73 99 LaOCl 94 0 71 13 100 99 24 92 7 0 96 96 La2(CO3)3.4H2O 98 1 78 5 100 99 16 11 23 0 48 71 Ti(CO3)2 91 98 97 96 24 100 100 92 100 0 99 98 TiO2 97 0 97 62 0 86 0 0 0 30 99 66 La2O(CO3)2.xH2O 99 0 79 8 100 99 16 60 26 0 44 74 La2O2CO3 99 34 81 12 100 99 100 92 23 0 87 99 - The most efficient compounds for removing both arsenic and selenium appear to be the titanium-based
compounds range 70 to 80%. Commercial lanthanum carbonate (4 in Table 6) is less effective. - The tests show that the lanthanum and titanium compounds made following the process of the present invention are also effective at removing Sb, Cr, Pb, Mo from solution. They also confirm the efficient removal of phosphorus discussed in the previous examples.
- While the invention has been described in conjunction with specific embodiments, it is to be understood that many alternatives, modifications, and variations will be apparent to those skilled in the art in light of the foregoing description. Accordingly, this invention is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and scope of the appended claims.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/181,609 US20060002837A1 (en) | 2002-05-24 | 2005-07-13 | Processes for making rare earth metal oxycarbonates |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39698902P | 2002-05-24 | 2002-05-24 | |
US40386802P | 2002-08-14 | 2002-08-14 | |
US43028402P | 2002-12-02 | 2002-12-02 | |
US46117503P | 2003-04-08 | 2003-04-08 | |
US10/444,774 US20040161474A1 (en) | 2002-05-24 | 2003-05-23 | Rare earth metal compounds methods of making, and methods of using the same |
US11/181,609 US20060002837A1 (en) | 2002-05-24 | 2005-07-13 | Processes for making rare earth metal oxycarbonates |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/444,774 Continuation US20040161474A1 (en) | 2002-05-24 | 2003-05-23 | Rare earth metal compounds methods of making, and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060002837A1 true US20060002837A1 (en) | 2006-01-05 |
Family
ID=31892259
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/444,774 Abandoned US20040161474A1 (en) | 2002-05-24 | 2003-05-23 | Rare earth metal compounds methods of making, and methods of using the same |
US11/181,650 Active 2025-07-15 US7588782B2 (en) | 2002-05-24 | 2005-07-13 | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US11/181,538 Abandoned US20050247628A1 (en) | 2002-05-24 | 2005-07-13 | Devices for removing phosphate from biological fluids |
US11/181,609 Abandoned US20060002837A1 (en) | 2002-05-24 | 2005-07-13 | Processes for making rare earth metal oxycarbonates |
US12/051,726 Abandoned US20080226735A1 (en) | 2002-05-24 | 2008-03-19 | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US12/197,157 Abandoned US20090053322A1 (en) | 2002-05-24 | 2008-08-22 | Rare earth metal compounds, methods of making, and methods of using the same |
US12/814,716 Abandoned US20100278910A1 (en) | 2002-05-24 | 2010-06-14 | Rare earth metal compounds, methods of making, and methods of using the same |
US13/018,894 Abandoned US20110123628A1 (en) | 2002-05-24 | 2011-02-01 | Rare earth metal compounds, methods of making, and methods of using the same |
US13/229,157 Abandoned US20110318410A1 (en) | 2002-05-24 | 2011-09-09 | Rare earth metal compounds, methods of making, and methods of using the same |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/444,774 Abandoned US20040161474A1 (en) | 2002-05-24 | 2003-05-23 | Rare earth metal compounds methods of making, and methods of using the same |
US11/181,650 Active 2025-07-15 US7588782B2 (en) | 2002-05-24 | 2005-07-13 | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US11/181,538 Abandoned US20050247628A1 (en) | 2002-05-24 | 2005-07-13 | Devices for removing phosphate from biological fluids |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/051,726 Abandoned US20080226735A1 (en) | 2002-05-24 | 2008-03-19 | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US12/197,157 Abandoned US20090053322A1 (en) | 2002-05-24 | 2008-08-22 | Rare earth metal compounds, methods of making, and methods of using the same |
US12/814,716 Abandoned US20100278910A1 (en) | 2002-05-24 | 2010-06-14 | Rare earth metal compounds, methods of making, and methods of using the same |
US13/018,894 Abandoned US20110123628A1 (en) | 2002-05-24 | 2011-02-01 | Rare earth metal compounds, methods of making, and methods of using the same |
US13/229,157 Abandoned US20110318410A1 (en) | 2002-05-24 | 2011-09-09 | Rare earth metal compounds, methods of making, and methods of using the same |
Country Status (15)
Country | Link |
---|---|
US (9) | US20040161474A1 (en) |
EP (1) | EP1529015A2 (en) |
JP (1) | JP4584830B2 (en) |
KR (1) | KR101108820B1 (en) |
AU (2) | AU2003268082A1 (en) |
BR (2) | BRPI0313737B1 (en) |
CA (1) | CA2494992C (en) |
DE (1) | DE03749033T1 (en) |
EA (3) | EA017083B1 (en) |
ES (1) | ES2311441T1 (en) |
HK (1) | HK1082242A1 (en) |
IL (1) | IL166803A0 (en) |
MX (1) | MXPA05001773A (en) |
SG (1) | SG173920A1 (en) |
WO (1) | WO2004016553A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
US20060083791A1 (en) * | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
US20060134225A1 (en) * | 2004-10-15 | 2006-06-22 | Moerck Rudi E | Phosphate binder with reduced pill burden |
EP2098882A2 (en) | 2008-03-04 | 2009-09-09 | Samsung Electronics Co., Ltd. | Location measurement method based on predictive filter |
US7618656B2 (en) | 2006-05-05 | 2009-11-17 | Shire International Licensing B.V. | Method for use of lanthanum carbonate pharmaceutical compositions |
US20100104664A1 (en) * | 2005-08-17 | 2010-04-29 | Allison Wren | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
US6863825B2 (en) | 2003-01-29 | 2005-03-08 | Union Oil Company Of California | Process for removing arsenic from aqueous streams |
US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
EA200970709A1 (en) * | 2003-08-26 | 2010-04-30 | Шир Холдингз Аг | PHARMACEUTICAL COMPOSITION CONTAINING LANTHANE COMPOUNDS |
EA010980B1 (en) | 2004-07-27 | 2008-12-30 | Шир Фармасьютикалс, Инк. | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
GB0502787D0 (en) * | 2005-02-10 | 2005-03-16 | Ineos Silicas Ltd | Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use |
EP1698233A1 (en) * | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
US20070023291A1 (en) * | 2005-07-15 | 2007-02-01 | Sai Bhavaraju | Metal Trap |
US7338603B1 (en) * | 2005-07-27 | 2008-03-04 | Molycorp, Inc. | Process using rare earths to remove oxyanions from aqueous streams |
DE06801934T1 (en) * | 2005-08-17 | 2009-01-15 | Altairnano, Inc., Reno | HYPERPHOSPHATEMIA IN PETS: COMPOSITIONS AND METHODS OF TREATMENT |
EP1951266A2 (en) | 2005-09-02 | 2008-08-06 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
JP5595660B2 (en) | 2005-09-15 | 2014-09-24 | ジェンザイム コーポレーション | Sachet formulation for amine polymer |
US20070104799A1 (en) * | 2005-11-09 | 2007-05-10 | Shire International Licensing B.V. | Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds |
CN100460058C (en) * | 2006-01-20 | 2009-02-11 | 王家强 | Modified natural and self-making floating carrier and mesopore molecular sieve denitrogen dephosphorus material, its preparation and application |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
JP2010504975A (en) | 2006-09-29 | 2010-02-18 | ゲンズイメ コーポレーション | Amide dendrimer composition |
JP2010513271A (en) | 2006-12-14 | 2010-04-30 | ゲンズイメ コーポレーション | Amide-amine polymer composition |
US8066874B2 (en) | 2006-12-28 | 2011-11-29 | Molycorp Minerals, Llc | Apparatus for treating a flow of an aqueous solution containing arsenic |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
US8252087B2 (en) | 2007-10-31 | 2012-08-28 | Molycorp Minerals, Llc | Process and apparatus for treating a gas containing a contaminant |
US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
US20100098768A1 (en) * | 2008-10-16 | 2010-04-22 | Clarkson University | Method of neuroprotection from oxidant injury using metal oxide nanoparticles |
US8962036B2 (en) | 2009-01-21 | 2015-02-24 | Mylan Pharmaceuticals Inc. | Disintegrable formulations of lanthanum carbonate |
US20110002971A1 (en) * | 2009-07-06 | 2011-01-06 | Molycorp Minerals, Llc | Ceria for use as an antimicrobial barrier and disinfectant in a wound dressing |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
EP2560702A2 (en) * | 2010-04-20 | 2013-02-27 | University of North Carolina | Adsorption devices, systems and methods |
US9402808B2 (en) | 2011-01-19 | 2016-08-02 | Panacea Biotec Limited | Liquid oral composition of lanthanum salts |
US9233863B2 (en) | 2011-04-13 | 2016-01-12 | Molycorp Minerals, Llc | Rare earth removal of hydrated and hydroxyl species |
CN102249283B (en) * | 2011-06-03 | 2012-12-12 | 北京化工大学 | Method for preparing highly-dispersed nano-sized lanthanum oxide by carbon black system |
WO2013184373A1 (en) | 2012-06-05 | 2013-12-12 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
JP6377130B2 (en) * | 2014-03-03 | 2018-08-22 | 株式会社マエダマテリアル | Adsorbent for water treatment, production method thereof, water treatment device, cartridge for water treatment device, and water treatment method |
CN106457073A (en) | 2014-03-07 | 2017-02-22 | 安全自然资源有限公司 | Cerium (iv) oxide with exceptional arsenic removal properties |
JP6225270B2 (en) * | 2014-10-02 | 2017-11-01 | 東和薬品株式会社 | Medicament comprising particle size-adjusted lanthanum carbonate hydrate |
CN104591254A (en) * | 2015-02-16 | 2015-05-06 | 包头市锦园化工科技有限公司 | Method for directly preparing rare earth chloride powder from rare earth chloride solution |
JP6874336B2 (en) * | 2015-11-30 | 2021-05-19 | 東レ株式会社 | Porous fiber and phosphorus adsorption column |
EP3777920A1 (en) * | 2015-11-30 | 2021-02-17 | Toray Industries, Inc. | Phosphorus adsorbent, porous fiber and phosphorus adsorption column |
CN106540722B (en) * | 2016-10-19 | 2019-03-22 | 常州大学 | A kind of preparation method of hollow structure yttrium phosphate catalyst |
RU2657755C1 (en) * | 2017-07-10 | 2018-06-15 | Александр Александрович Кролевец | Method for producing nanocapules of lanthanoid salts in carrageenan |
EP4027136B1 (en) | 2018-07-13 | 2023-10-04 | Fuji Electric Co., Ltd. | Carbon dioxide gas sensor |
CN111115675B (en) * | 2018-10-11 | 2023-03-10 | 有研稀土新材料股份有限公司 | High-purity light lanthanum carbonate or lanthanum oxide and preparation method thereof |
JPWO2020085438A1 (en) * | 2018-10-24 | 2021-09-16 | 三井金属鉱業株式会社 | Adsorbent, its manufacturing method, and adsorption molded product |
JP7174967B2 (en) * | 2019-09-19 | 2022-11-18 | 国立大学法人神戸大学 | phosphorus adsorbent |
CN111744454A (en) * | 2020-06-02 | 2020-10-09 | 河北科技师范学院 | Preparation method of composite phosphorus removal adsorbent lanthanum oxycarbonate loaded montmorillonite |
CN116675242A (en) * | 2021-05-12 | 2023-09-01 | 中国北方稀土(集团)高科技股份有限公司 | Method for preparing hexagonal system lanthanum hydroxycarbonate by adopting hydrothermal synthesis |
CN113813916B (en) * | 2021-09-17 | 2024-02-02 | 交通运输部天津水运工程科学研究所 | Salt-tolerant deep dephosphorizing agent and preparation method thereof |
CN114100561B (en) * | 2021-12-01 | 2023-05-02 | 中国科学院生态环境研究中心 | Metal modified La 2 O 2 CO 3 Adsorbent, and preparation method and application thereof |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692671A (en) * | 1970-10-01 | 1972-09-19 | North American Rockwell | Rare earth ion removal from waste water |
US3768989A (en) * | 1968-08-19 | 1973-10-30 | N Goetzinger | Process for the preparation of a rare earth oxide polishing composition |
US3922331A (en) * | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
US4462970A (en) * | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
US4929787A (en) * | 1987-08-05 | 1990-05-29 | Institut Francais Du Petrole | Process for converting methane to higher hydrocarbons |
US5407560A (en) * | 1992-03-16 | 1995-04-18 | Japan Energy Corporation | Process for manufacturing petroleum cokes and cracked oil from heavy petroleum oil |
US5782792A (en) * | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
US5968976A (en) * | 1995-03-25 | 1999-10-19 | Anormed Inc. | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
US6146539A (en) * | 1993-02-24 | 2000-11-14 | Dudley Mills Pty Ltd | Treatment of swimming pool water |
US6197201B1 (en) * | 1998-07-29 | 2001-03-06 | The Board Of Regents Of The University & Community College System Of Nevada | Process for removal and stabilization of arsenic and selenium from aqueous streams and slurries |
US6312604B1 (en) * | 1998-10-23 | 2001-11-06 | Zodiac Pool Care, Inc. | Lanthanide halide water treatment compositions and methods |
US6322895B1 (en) * | 1995-08-03 | 2001-11-27 | Qinetiq Limited | Biomaterial |
US6338800B1 (en) * | 2000-02-22 | 2002-01-15 | Natural Chemistry, Inc. | Methods and compositions using lanthanum for removing phosphates from water |
US20020035151A1 (en) * | 1999-12-22 | 2002-03-21 | Deluca Hector F. | Calcium formate for use as a dietary supplement |
US6376479B1 (en) * | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US553900A (en) * | 1896-02-04 | Electrical whistle-controlling device | ||
SU424815A1 (en) * | 1972-03-28 | 1974-04-25 | В. И. Быстрое, В. А. Соколов, Л. Г. Пинаева , Н. М. Шмыгуль | METHOD FOR PRODUCING TITANIUM DIOXIDE |
US3922333A (en) * | 1973-06-04 | 1975-11-25 | Us Air Force | Process for preparing mullite powder and fabrication of structural bodies therefrom |
US4240048A (en) * | 1978-12-15 | 1980-12-16 | E. I. Du Pont De Nemours & Co. | Nonlinear optical device |
DE3066207D1 (en) * | 1980-11-14 | 1984-02-23 | Rudolf Schanze | Concentrate containing trace elements suitable for men and animals, method for its preparation and utilization thereof |
US4497785A (en) * | 1983-11-18 | 1985-02-05 | Union Oil Company Of California | Production of rare earth compounds |
JPS60226414A (en) * | 1984-04-20 | 1985-11-11 | Hitachi Ltd | Production of lanthanum-alumina based compound oxide |
JPS614529A (en) * | 1984-06-15 | 1986-01-10 | Asahi Chem Ind Co Ltd | Adsorbent of phosphoric acid ion |
JPH06705B2 (en) * | 1985-12-19 | 1994-01-05 | 旭化成工業株式会社 | Phosphate ion fixing agent |
JPH01301517A (en) * | 1988-05-30 | 1989-12-05 | Catalysts & Chem Ind Co Ltd | Production of titanium dioxide-cerium oxide multiple sol and cosmetic blended with same |
FR2634398B1 (en) * | 1988-06-29 | 1990-09-07 | Elf Aquitaine | PROCESS FOR THE PREPARATION OF A CATALYST CAPABLE OF PROMOTING THE OXIDIZING CONVERSION OF METHANE INTO SUPERIOR HYDROCARBONS |
GB9201857D0 (en) * | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
EP0604919A1 (en) * | 1992-12-28 | 1994-07-06 | Ishihara Sangyo Kaisha, Ltd. | Deodorant |
US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
MY131700A (en) * | 1993-11-24 | 2007-08-30 | Kerr Mcgee Ct Llc | Durable pigmentary titanium dioxide and methods of producing the same |
JPH0810610A (en) * | 1994-07-05 | 1996-01-16 | Ishihara Sangyo Kaisha Ltd | Phosphorus adsorbent |
JP2843909B2 (en) * | 1996-05-27 | 1999-01-06 | 科学技術庁無機材質研究所長 | Method for producing yttrium oxide transparent sintered body |
JP3081910B2 (en) * | 1997-08-07 | 2000-08-28 | 工業技術院長 | Arsenic (V) ion removal method |
GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
US5843477A (en) * | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
JP3985111B2 (en) * | 1998-04-09 | 2007-10-03 | 第一稀元素化学工業株式会社 | Method for producing zirconia-ceria composition |
US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
JP4565704B2 (en) * | 2000-05-23 | 2010-10-20 | 三井金属鉱業株式会社 | High purity holmium oxide and method for producing the same |
GB0015745D0 (en) * | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
JP3407039B2 (en) * | 2000-07-10 | 2003-05-19 | 独立行政法人産業技術総合研究所 | Arsenic-contaminated soil cleaner, arsenic-contaminated soil stabilizer, and method for remediating arsenic-contaminated soil using the same |
US6403523B1 (en) * | 2000-09-18 | 2002-06-11 | Union Carbide Chemicals & Plastics Technology Corporation | Catalysts for the oxidative dehydrogenation of hydrocarbons |
FR2820134A1 (en) | 2001-01-29 | 2002-08-02 | Rhodia Elect & Catalysis | RARE EARTH OXYCHLORIDE WITH A HIGH SPECIFIC SURFACE, ITS PREPARATION METHODS AND ITS USE AS A CATALYST |
US6849609B2 (en) * | 2001-04-10 | 2005-02-01 | James U. Morrison | Method and composition for controlled release acarbose formulations |
NZ532097A (en) * | 2001-09-28 | 2006-02-24 | Mcneil Ppc Inc | Dosage forms having an inner core and outer shell |
US7119120B2 (en) * | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
WO2003094933A2 (en) | 2002-05-08 | 2003-11-20 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
US20060083791A1 (en) * | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
EP1567451A2 (en) * | 2002-12-02 | 2005-08-31 | Altair Nanomaterials Inc. | Rare earth compositions and structures for removing phosphates from water |
EA200970709A1 (en) * | 2003-08-26 | 2010-04-30 | Шир Холдингз Аг | PHARMACEUTICAL COMPOSITION CONTAINING LANTHANE COMPOUNDS |
US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
EA010980B1 (en) * | 2004-07-27 | 2008-12-30 | Шир Фармасьютикалс, Инк. | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
JP2008516971A (en) * | 2004-10-15 | 2008-05-22 | アルテアーナノ,インコーポレーテッド | Phosphate binder that reduces the burden of tablets |
JP2009504779A (en) * | 2005-08-17 | 2009-02-05 | アルテアナノ インコーポレイテッド | Treatment of chronic renal failure and other illnesses in livestock: compositions and methods |
DE06801934T1 (en) * | 2005-08-17 | 2009-01-15 | Altairnano, Inc., Reno | HYPERPHOSPHATEMIA IN PETS: COMPOSITIONS AND METHODS OF TREATMENT |
-
2003
- 2003-05-23 US US10/444,774 patent/US20040161474A1/en not_active Abandoned
- 2003-08-08 EA EA200800021A patent/EA017083B1/en not_active IP Right Cessation
- 2003-08-08 EA EA200500352A patent/EA009766B1/en not_active IP Right Cessation
- 2003-08-08 BR BRPI0313737-6A patent/BRPI0313737B1/en active IP Right Grant
- 2003-08-08 MX MXPA05001773A patent/MXPA05001773A/en active IP Right Grant
- 2003-08-08 DE DE03749033T patent/DE03749033T1/en active Pending
- 2003-08-08 ES ES03749033T patent/ES2311441T1/en active Pending
- 2003-08-08 BR BRPI0313737A patent/BRPI0313737B8/en active Search and Examination
- 2003-08-08 CA CA2494992A patent/CA2494992C/en not_active Expired - Lifetime
- 2003-08-08 JP JP2005502047A patent/JP4584830B2/en not_active Expired - Lifetime
- 2003-08-08 KR KR1020057002491A patent/KR101108820B1/en active IP Right Grant
- 2003-08-08 EA EA200800020A patent/EA012877B1/en not_active IP Right Cessation
- 2003-08-08 SG SG2007009418A patent/SG173920A1/en unknown
- 2003-08-08 EP EP03749033A patent/EP1529015A2/en not_active Ceased
- 2003-08-08 AU AU2003268082A patent/AU2003268082A1/en not_active Abandoned
- 2003-08-08 WO PCT/US2003/025192 patent/WO2004016553A2/en active Application Filing
-
2005
- 2005-02-10 IL IL166803A patent/IL166803A0/en not_active IP Right Cessation
- 2005-07-13 US US11/181,650 patent/US7588782B2/en active Active
- 2005-07-13 US US11/181,538 patent/US20050247628A1/en not_active Abandoned
- 2005-07-13 US US11/181,609 patent/US20060002837A1/en not_active Abandoned
-
2006
- 2006-04-11 HK HK06104369.9A patent/HK1082242A1/en not_active IP Right Cessation
-
2008
- 2008-03-19 US US12/051,726 patent/US20080226735A1/en not_active Abandoned
- 2008-08-22 US US12/197,157 patent/US20090053322A1/en not_active Abandoned
-
2009
- 2009-11-17 AU AU2009238282A patent/AU2009238282B2/en not_active Expired
-
2010
- 2010-06-14 US US12/814,716 patent/US20100278910A1/en not_active Abandoned
-
2011
- 2011-02-01 US US13/018,894 patent/US20110123628A1/en not_active Abandoned
- 2011-09-09 US US13/229,157 patent/US20110318410A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3768989A (en) * | 1968-08-19 | 1973-10-30 | N Goetzinger | Process for the preparation of a rare earth oxide polishing composition |
US3692671A (en) * | 1970-10-01 | 1972-09-19 | North American Rockwell | Rare earth ion removal from waste water |
US3922331A (en) * | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
US4462970A (en) * | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
US5782792A (en) * | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
US4929787A (en) * | 1987-08-05 | 1990-05-29 | Institut Francais Du Petrole | Process for converting methane to higher hydrocarbons |
US5407560A (en) * | 1992-03-16 | 1995-04-18 | Japan Energy Corporation | Process for manufacturing petroleum cokes and cracked oil from heavy petroleum oil |
US6146539A (en) * | 1993-02-24 | 2000-11-14 | Dudley Mills Pty Ltd | Treatment of swimming pool water |
US5968976A (en) * | 1995-03-25 | 1999-10-19 | Anormed Inc. | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
US6376479B1 (en) * | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6322895B1 (en) * | 1995-08-03 | 2001-11-27 | Qinetiq Limited | Biomaterial |
US6197201B1 (en) * | 1998-07-29 | 2001-03-06 | The Board Of Regents Of The University & Community College System Of Nevada | Process for removal and stabilization of arsenic and selenium from aqueous streams and slurries |
US6312604B1 (en) * | 1998-10-23 | 2001-11-06 | Zodiac Pool Care, Inc. | Lanthanide halide water treatment compositions and methods |
US20020035151A1 (en) * | 1999-12-22 | 2002-03-21 | Deluca Hector F. | Calcium formate for use as a dietary supplement |
US6338800B1 (en) * | 2000-02-22 | 2002-01-15 | Natural Chemistry, Inc. | Methods and compositions using lanthanum for removing phosphates from water |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100196485A1 (en) * | 2002-05-24 | 2010-08-05 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US20050247628A1 (en) * | 2002-05-24 | 2005-11-10 | Moerck Rudi E | Devices for removing phosphate from biological fluids |
US20060003018A1 (en) * | 2002-05-24 | 2006-01-05 | Moerck Rudi E | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US20060083791A1 (en) * | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
US9511091B2 (en) | 2002-05-24 | 2016-12-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US7588782B2 (en) | 2002-05-24 | 2009-09-15 | Altairnano, Inc. | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US8852543B2 (en) | 2002-05-24 | 2014-10-07 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US8715603B2 (en) | 2002-05-24 | 2014-05-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US20100278910A1 (en) * | 2002-05-24 | 2010-11-04 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US20060134225A1 (en) * | 2004-10-15 | 2006-06-22 | Moerck Rudi E | Phosphate binder with reduced pill burden |
US20100119602A1 (en) * | 2004-10-15 | 2010-05-13 | Spectrum Pharmaceuticals, Inc. | Phosphate binder with reduced pill burden |
US20100104664A1 (en) * | 2005-08-17 | 2010-04-29 | Allison Wren | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
US20100092576A1 (en) * | 2006-05-05 | 2010-04-15 | Shire International Licensing B.V. | Pharmaceutical compositions containing lanthanum hydroxycarbonate |
US7618656B2 (en) | 2006-05-05 | 2009-11-17 | Shire International Licensing B.V. | Method for use of lanthanum carbonate pharmaceutical compositions |
EP2098882A2 (en) | 2008-03-04 | 2009-09-09 | Samsung Electronics Co., Ltd. | Location measurement method based on predictive filter |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US10350240B2 (en) | 2010-05-12 | 2019-07-16 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US11406663B2 (en) | 2010-05-12 | 2022-08-09 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7588782B2 (en) | Rare earth metal compositions for treating hyperphosphatemia and related methods | |
US9511091B2 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
AU2003298800B2 (en) | Rare earth compositions and structures for removing phosphates from water | |
RU2420297C2 (en) | Pharmaceutically active compounds, their obtaining, compositions containing them and their application | |
CN100526219C (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
EP2194028B1 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
ES2907070T3 (en) | Rare earth metal compounds, methods of manufacture and methods of use thereof | |
JP5352411B2 (en) | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient | |
AU2008200837A1 (en) | Rare earth compositions and structures for removing phosphates from water |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALTAIRNANO, INC., NEVADA Free format text: CHANGE OF NAME;ASSIGNOR:ALTAIR NANOMATERIALS, INC.;REEL/FRAME:018297/0669 Effective date: 20060707 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: SPECTRUM PHARAMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALTAIR NANOMATERIALS, INC.;REEL/FRAME:023463/0676 Effective date: 20091029 |
|
AS | Assignment |
Owner name: SPECTRUM PHARMACEUTALS, INC., CALIFORNIA Free format text: CORRECTION TO REEL FRAME 023463/0076 - CORRECTION TO ASSIGNEE'S NAME AND CORRECTION TO LANGUGAGE CONTAINED IN THE BODY OF THE ASSIGNMENT DOCUMENT;ASSIGNOR:ALTAIRNANO, INC.;REEL/FRAME:024910/0439 Effective date: 20091029 |
|
AS | Assignment |
Owner name: SPECTRUM PHARMACEUTICALS, INC., CALIFORNIA Free format text: CORRECTIVE ASSIGNEMENT TO CORRECT SPELLING OF ASSGNEE'S NAME PROVIOUSLY RECORDED ON REEL 024910 FRAME 0439;ASSIGNOR:ALTAIRNANO, INC.;REEL/FRAME:025057/0430 Effective date: 20091029 |